Muscle Weakness in Persons with Multiple Sclerosis by Chung, Linda Haiwon
University of Massachusetts Amherst
ScholarWorks@UMass Amherst
Open Access Dissertations
9-2010
Muscle Weakness in Persons with Multiple
Sclerosis
Linda Haiwon Chung
University of Massachusetts Amherst, lindah.chung@gmail.com
Follow this and additional works at: https://scholarworks.umass.edu/open_access_dissertations
Part of the Kinesiology Commons
This Open Access Dissertation is brought to you for free and open access by ScholarWorks@UMass Amherst. It has been accepted for inclusion in
Open Access Dissertations by an authorized administrator of ScholarWorks@UMass Amherst. For more information, please contact
scholarworks@library.umass.edu.
Recommended Citation
Chung, Linda Haiwon, "Muscle Weakness in Persons with Multiple Sclerosis" (2010). Open Access Dissertations. 268.
https://scholarworks.umass.edu/open_access_dissertations/268
 
 
 
 
 
 
MUSCLE WEAKNESS IN PERSONS WITH MULTIPLE SCLEROSIS 
 
 
 
 
 
 
 
A Dissertation Presented  
 
by 
 
LINDA H. CHUNG 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate School of the 
University of Massachusetts Amherst in partial fulfillment 
of the requirements for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
 
September 2010 
 
Kinesiology 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Copyright by Linda H. Chung 2010 
 
All Rights Reserved 
  
 
 
 
MUSCLE WEAKNESS IN PERSONS WITH MULTIPLE SCLEROSIS 
 
 
 
 
 
 
A Dissertation Presented 
 
by 
 
LINDA H. CHUNG 
 
 
 
 
 
Approved as to style and content by: 
 
 
____________________________________ 
Jane A. Kent-Braun, Chair 
 
 
____________________________________ 
Richard E. van Emmerik, Member 
 
 
____________________________________ 
Gary Kamen, Member 
 
 
____________________________________ 
John Staudenmayer, Member 
 
 
 
__________________________________________ 
Patty Freedson, Department Head 
Department of Kinesiology 
  
  
DEDICATION 
 
I dedicate this work to my family and Bernabé, who have always encouraged me 
to pursue great things.  It is because of you guys that I have never stopped challenging 
myself and have reached this fantastic milestone in my academic career. 
 
 ACKNOWLEDGMENTS 
For what seemed like an eternity to reach this major milestone, I have finally 
made it.  The funny thing is it feels like it came too quickly.  But I suppose that is what 
happens when you are surrounded by an amazing group of faculty and colleagues, all of 
whom have made me feel like a part of a family and whom I call my greatest friends.  
Thank you to my committee members for your unconditional support throughout this 
dissertation process.  Thank you to the faculty and peers in the Department of 
Kinesiology for your support and unwavering enthusiasm.  Special thank you to 
Stephen Foulis, Damien Callahan, Ryan Larsen, Ian Lanza, Danielle Wigmore, Mike 
Tevald and Anita Christie for your assistance in data collection, intellectual discussions, 
fond memories, and just good fun.   
And last, but not least, a big THANK YOU to Jane Kent-Braun.  Never have I 
ever had such an amazing advisor, who has guided me intellectually and supported me 
in my academic endeavors.  You have provided me the confidence to take on anything 
that crosses my path.  Thank you for being a great mentor and for showing me that one 
can have fun at work too.  You are simply the best. 
 
 v
 ABSTRACT 
MUSCLE WEAKNESS IN PERSONS WITH MULTIPLE SCLEROSIS 
 
SEPTEMBER 2010 
 
LINDA H. CHUNG, B.S., UNIVERSITY OF OREGON 
 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Ph.D. Candidate, UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Jane A. Kent-Braun 
 
Skeletal muscle weakness is a problem for people living with Multiple Sclerosis 
(MS).  Alterations in the central nervous system may be the primary source of muscle 
weakness because of the pathophysiology of MS.  However, changes in peripheral 
mediators of force production may also contribute to muscle weakness in persons with 
MS.  The main objective of the dissertation was to systematically identify key neural 
(motor unit discharge rates, spasticity) and muscular (muscle size, contractile function) 
mechanisms of force production that may explain lower isometric strength and dynamic 
power in persons with MS compared with age-matched controls.  The knee extensor 
muscles of the weaker leg were studied, because this muscle group is commonly 
affected by MS. 
We showed that persons with MS had lower peak isometric torque and dynamic 
power compared with controls.  Persons with MS had lower motor unit discharge rates, 
smaller muscle size, and lower specific power compared with controls.  There was no 
difference in passive torque (spasticity), specific strength, or maximal rate of force 
development between groups.   Because differences in isometric strength between 
persons with MS and controls were abolished when torque was normalized to muscle 
 vi
 size, smaller muscle size may explain a large portion of lower isometric strength in 
persons with MS.  Differences in dynamic power were reduced when peak power was 
normalized to muscle size, but remained lower in persons with MS compared with 
controls, suggesting that changes in neural factors (e.g., lower motor unit discharge 
rates) may explain lower dynamic power in persons with MS.  These results suggest 
that different mechanisms may contribute to muscle weakness in MS, depending on the 
mode of contraction.   
Lower motor unit discharge rates and smaller muscle size were identified as key 
mechanisms of muscle weakness in persons with MS.  Each of these mechanisms has 
been shown to improve with resistance training in controls.  Thus, this dissertation 
provides an evidence-based rationale for resistance training interventions in persons 
with MS, to improve isometric strength and power production by increasing motor unit 
discharge rates and muscle size. 
 
 vii
 PREFACE 
Chapters 1 through 4 include the dissertation proposal, as submitted to the 
Graduate School in June 2009.  In addition to the original proposal, the manuscript of 
Study 1 is included (Chapter 5).  During a meeting with the dissertation committee in 
October 2009, it was decided that Study 2 would no longer be conducted as part of the 
dissertation.  The reasons for this decision were first, Study 2 could not be undertaken 
until the completion of Study 1, which would provide the foundational evidence and 
rationale for Study 2; and second, an unreasonable amount of time would be needed to 
process and analyze the data from Study 1.  Together, these factors rendered Study 2 
impractical for inclusion in the dissertation.  Rather, it was decided at this meeting to 
include a complementary study examining the energy cost of walking in persons with 
MS, which was not originally proposed in the dissertation.  The manuscript for the 
energy cost of walking study is included as Appendix A.   
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CHAPTER 1   
INTRODUCTION 
Multiple Sclerosis 
Multiple Sclerosis (MS) is an auto-immune disease affecting the central nervous 
system, which includes the brain and spinal cord.  It has been estimated that 400,000 
people in the United States and 2.5 million people worldwide are living with MS 
(National Multiple Sclerosis Society).  Although the etiology of MS is unknown, 
environmental, infectious, and genetic factors are currently being investigated as 
possible causes of MS (54).  Diagnosis of MS typically occurs in the second or third 
decade of life, and women are twice more likely to develop MS than men.  The defining 
feature of MS is demyelination of nerves by T-cells, which disrupts the neural 
conduction of signals from the central nervous system to effector organs.  As a result, 
inappropriate neural activity may lead to the onset of symptoms, such as muscle 
weakness and loss of postural control.   
There are different forms of MS: primary progressive, relapsing-remitting, 
secondary progressive, and progressive relapsing.  About 20% of initial diagnoses are 
primary progressive, which is characterized by a slow, continual worsening of 
symptoms.  The most common form of initial diagnosis (~80%) is relapsing-remitting; 
people with this type of MS experience acute exacerbations of symptoms with periods 
of recovery.  Within 10 years of diagnosis, about 50% of those who were initially 
diagnosed as relapsing-remitting will become secondary progressive, thus, transitioning 
to the characteristics of the primary progressive form.  A rare form of MS is progressive 
 relapsing, which is a combination of the primary progressive and relapsing-remitting 
forms.   
The diagnosis of MS follows stringent criteria (89), as symptoms may overlap 
with other pathologies.  Therefore, confirmation of MS may take up to several weeks 
from the onset of symptoms.  Recent technological advances (i.e., magnetic resonance 
imaging with gadolinium enhancement) have allowed for earlier diagnosis of MS (89).  
Clinical assessments include spinal taps and evoked potential tests.  Spinal taps are 
collected samples of cerebrospinal fluid, which is used to determine the number or 
pattern of immunoglobulins that indicate the level of the immune response.  Evoked 
potential tests of the visual, auditory, or somatosensory systems are performed to 
measure the magnitude and detection time of an electrical response to a given stimulus, 
which provides some insight to the quality of the nervous system. 
The demyelination and sclera1 that define MS can develop anywhere in the 
white matter of the central nervous system.  For that reason, MS is not limited to a 
particular region of the central nervous system.  Common symptoms in MS include: 
changes in cognitive function, depression, symptomatic fatigue, muscle weakness, 
spasticity, dizziness, vertigo, vision problems, bladder and bowel dysfunction, difficulty 
in walking, balance problems, abnormal sensations, and pain (National Multiple 
Sclerosis Society).  These detrimental symptoms may have a major impact on activities 
of daily living and overall quality of life in persons with MS.   
                                                 
1 sclera - scarring 
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 Factors That Influence Muscle Strength and Power 
Force generation is the product of a series of events that begins at the motor 
cortex of the brain and ends with the cycling of cross-bridges between myofilaments 
within the muscle.  Impairments at any point along this pathway of force production 
may result in a decline in muscle strength2 and power3.  Central factors of force 
production include the recruitment of motor units4, rate coding5, and adequate 
transmission of action potentials6 to the muscle.   
There are a number of peripheral factors that may influence force production.  
Processes at the neuromuscular junction, such as the conversion of an electrical signal 
(action potential) to a chemical signal (acetylcholine), must be functioning.  Excitability 
of the muscle membrane and propagation of the action potential along the muscle 
membrane and into the transverse-tubules are important in activating the muscle.  
Within the muscle, the rate of calcium release from the sarcoplasmic reticulum 
modulates the development of force production.  Myosin ATPase activity, which is 
important in cross-bridge cycling, can affect the shortening velocity of contracting 
muscle fibers. 
In addition to the aforementioned pathway, strength and power are also 
influenced by muscle size.  Strength is partially affected by the number of muscle fibers 
in parallel, which is represented by muscle cross-sectional area (128).   Power is 
                                                 
2 strength – isometric torque 
3 power – product of torque and velocity 
4 motor unit – a motor neuron and all of the muscle fibers it innervates 
5 rate coding – modulation of motor unit firing rates 
6 action potentials – nerve impulses 
 3
 partially determined by the number of sarcomeres7 in series, which affects the maximal 
shortening velocity of a muscle fiber (128).  Since fiber types differ in contractile 
velocity, fiber type distribution within a muscle may also influence power.  The order of 
fiber types from slowest to fastest is: type I < type IIa < type IIx.   
Skeletal Muscle Weakness in Persons with MS 
One of the major problems for people with MS is muscle weakness.  Lower 
extremity muscles are more affected by muscle weakness than upper extremity muscles 
in persons with MS (111).  The decrease in torque in persons with MS ranges from 16 
to 57% during both isometric (18; 80; 82; 83; 111; 113) and dynamic (3; 16; 21; 63; 99; 
121) contractions.  Reduced torque in persons with MS is often observed during 
dynamic contractions at high velocities (3; 45; 63; 99), suggesting the potential for 
power loss during high velocity contractions.  Power asymmetry8 in the knee extensors 
is also observed in persons with MS (21).   
The primary mechanism of muscle weakness may be central in nature and may 
be directly affected by the pathophysiology of MS.  Demyelination of neuronal axons 
may prolong corticomotoneuron conduction time9, which is observed in persons with 
MS (50; 123).  Central activation of the muscle (82; 106; 113) and specific strength10 
(82) are lower in persons with MS (82; 106; 113) and may be a result of lower motor 
unit firing rates (33; 106) or poor motor unit recruitment.   
                                                 
7 sarcomeres – the basic contractile units of the muscle fiber 
8 Power asymmetry – one leg being more powerful than the other leg 
9 Corticomotoneuron conduction time – the time it takes for the nerve impulse to travel from the brain 
to the muscle 
10 specific strength – the ratio of maximal voluntary force and the largest muscle cross-sectional area of 
the whole muscle 
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 Over time, these central changes may affect peripheral mediators of force 
production, such as muscle size, fiber type distribution, contractile function, and 
processes at the neuromuscular junction11.  A decline in muscle cross-sectional area and 
altered processes at the neuromuscular junction would impact strength, while shifts in 
fiber type distribution and changes in contractile function may affect power.  
Spasticity12 may also contribute to power declines in persons with MS.   
There is some evidence that muscle atrophy occurs in persons with MS at both 
the whole muscle (57) and muscle fiber (44; 57) levels.  However, the decrease in 
muscle size is not always observed in persons with MS (16; 82).  There are discrepant 
findings with regard to fiber type distribution shifts in persons with MS, which may 
affect the velocity component of power.  Persons with MS show either a higher 
percentage of type II fibers and lower percentage of type I fibers (57) or a lower 
percentage of type IIa fibers (44) compared to non-MS controls.  Studies using 
electrical stimulation show that the rate of force development is similar (28; 30) or 
lower (82; 113) in persons with MS compared to non-MS controls, suggesting possible 
alterations in contractile function that may impede power production.   However, at the 
muscle fiber level, unloaded shortening velocity (44) and myosin ATPase activity13 
(17) are similar between persons with MS and non-MS controls, indicating that 
contractile function is unaltered in persons with MS.  Processes at the neuromuscula
junction, such as those that are involved in muscle membrane excitability, may be 
r 
                                                 
11 processes at the neuromuscular junction - these include, but not limited to, neurotransmitter release 
from the axon terminal and muscle membrane excitability 
12 Spasticity – characterized as “a velocity-dependent resistance to passive stretch by the antagonist 
muscle due to the hyperexcitability of the stretch reflex” (64) 
13 myosin ATPase activity – enzyme that hydrolyzes ATP to promote the “power stroke” of the myosin 
head, which drives cross-bridge cycling 
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 altered in persons with MS.  Prolonged recovery of the compound muscle action 
potential magnitude, a measure of muscle membrane excitability, following loca
treatment is observed in persons with MS (34).   
l curare 
                                                
Power deficits in persons with MS may also be explained by spasticity, which is 
another major symptom in MS.  Spasticity is characterized as “a velocity-dependent 
resistance to passive stretch by the antagonist muscle due to the hyperexcitability of the 
stretch reflex”14 (64).  Thus, co-activation15 of the antagonist muscle due to spasticity 
may slow the contraction velocity and lower power production of the agonist muscle, 
especially during high contraction speeds.  Although spasticity is commonly assessed 
using subjective tests16, very few studies have used quantitative measures of spasticity 
in persons with MS (88).  Further, the role of spasticity in power production in persons 
with MS is not known.   
By and large, there are a number of potential mechanisms that contribute to 
muscle weakness in persons with MS.  The extent to which each of these mechanisms 
contributes to overall strength and power declines in persons with MS is not clear.  
Certainly, changes in the central mediators of force production may be the primary 
mechanisms of muscle weakness in persons with MS.  However, there may be 
additional contributions from peripheral mediators, such as muscle atrophy and slower 
contractile function, that may explain strength and power declines in persons with MS.  
 
14 stretch reflex – muscles spindles that detect changes in muscle length and stretch velocity excite the α-
motor neuron of the agonist muscle from which the muscle spindles lie, while inhibiting the α-motor 
neuron of the antagonist muscle, thus preventing any further stretching of the muscle (Figure 1.1 
describes the circuitry of the stretch reflex) 
15 co-activation – as the agonist muscle performs a dynamic contraction, the muscle spindles of the 
stretched antagonist muscle becomes activated, and through the stretch reflex, the antagonist muscle 
becomes excited while the agonist muscle becomes inhibited 
16 subjective tests – Ashworth or Modified Ashworth Scale (11) 
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 Although central changes may affect peripheral mediators of force production, 
peripheral changes may also be a result of lower physical activity levels, which are 
observed in persons with MS (57; 81).  Further, spasticity of antagonist muscles may 
play a role in lower power production in persons with MS.  No studies have 
systematically examined a variety of potential mechanisms of muscle weakness in the 
same group of people with MS. 
Postural Control in Persons with MS 
Adequate integration and coordination of sensory and motor processes is 
important in postural control.  The central nervous system receives input from sensory 
receptors regarding the body’s position in space via visual, vestibular, proprioceptive, 
and tactile cues, and processes this information to appropriately send motor commands 
to skeletal muscles, so that balance is maintained.  Impairments in sensory reception, 
delivery of sensory input to the central nervous system, perception of sensory input in 
the brain, appropriate decision-making with regard to motor commands, and delivery of 
motor output to skeletal muscle may disrupt postural control. 
Balance problems are another major symptom in MS, and there is a high 
incidence of falls in ~52% of MS patients (36).  About 45% of MS patients use assistive 
devices for mobility, particularly those with a progressive type of MS (35).  Some of the 
postural imbalances in persons with MS may be due, in part, to muscle weakness.  Poor 
postural control may also be due to lesions that interfere with central processes that 
mediate postural control.   
Postural control is commonly assessed using subjective measures.  Clinical 
balance tests challenge patients to maintain postural control for 30 s during semi-
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 tandem, tandem, and single-legged stances.  These tests reveal that persons with MS 
have difficulty with tandem and single leg stances (42; 116).  In addition, persons with 
MS have poorly controlled balance responses to external perturbations (42).  Lower 
physical activity levels shown in persons with MS (44; 57) may, partially, be explained 
by impairments in postural control. 
Ground reaction forces17 are used to calculate quantitative measures of postural 
control, such as the center of pressure variability (130) and time-to-contact (105), in the 
anterior-posterior (AP) and medio-lateral (ML) directions.  During quiet stance, the net 
center of pressure includes the time series of both the active ground reaction forces and 
the body’s center of mass projected on the ground (124; 130).  The center of pressure 
variability is the spatial18 representation of postural sway over time.  The time-to-
contact incorporates both spatial and temporal19 aspects of postural sway, either from 
the center of pressure or center of mass, with respect to the base of support20 over time.   
The center of pressure displacement during maximal leaning in the AP direction 
is lower in persons with MS compared to non-MS controls (53), indicating smaller 
boundary limits of stability in persons with MS.  The center of pressure variability in 
the AP direction during quiet stance is greater in women with MS compared to women 
without MS (21), suggesting poor postural control in women with MS.  Conditions 
challenging the sensory system (visual, somatosensory, vestibular, proprioception) 
show greater postural sway angles (79) and velocities (47) in persons with MS, 
especially when relying on the vestibular system alone.   
                                                 
17 ground reaction forces – measured forces, using a force plate, that are equal and opposite of the 
forces that are exerted by the feet 
18 spatial - displacement 
19 temporal – velocity and acceleration 
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 Although measuring the center of pressure provides some information with 
regard to postural control, it does not fully describe the dynamics of postural stability21 
in relation to the base of support.  Time-to-contact may be a better measure for studying 
postural control in persons with MS, as it provides both temporal and spatial 
components of center of mass with respect to the stability limits22 during a given task.  
Time-to-contact is the estimated time a person would take to reach one’s stability limit 
before falling.  There is limited information about time-to-contact as a measure of 
postural sway in persons with MS.  Postural studies in the elderly (39; 124) and 
Parkinson’s Disease patients (125) show reduced time-to-contact compared to healthy 
controls. 
Muscle strength is important in postural control (77; 109), especially during 
conditions when sensory systems are altered (66).  A correlation between muscle 
strength and postural sway is observed in Parkinson’s Disease patients (77) and in 
stroke patients (66).  Power asymmetry in the knee extensors is correlated with center of 
pressure variability in persons with MS (21).  Bilateral resistance training of the knee 
extensors has shown increases in the percentage limits of stability23 during leaning trials 
in multiple directions in middle-aged and elderly adults (109).  However, few studies 
have looked at the potential improvements in postural stability due to resistance training 
in persons with MS.  These studies convey the importance of muscle strength and 
power on postural control.   
                                                                                                                                               
20 base of support – area around the feet 
21 dynamics of postural stability – displacement of center of mass, velocity and acceleration of 
displacement of the center of mass  
22 stability limits – base of support 
23 percentage limits of stability – the furthest distance in which the center of gravity traveled from the 
mid-point with respect to the theoretical limits of stability computed by the Balance Master System 
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 Overall, postural control is impaired in persons with MS.  The examination of 
time-to-contact may be useful in understanding the dynamics of postural instability in 
persons with MS.  The association between postural control and muscle strength needs 
further investigation in persons with MS, as these two systems are tightly coupled via 
the descending pathway of force production.  Because MS presents impairments in 
central activation of the muscle, this may also affect postural control. 
Strength Training in Persons with MS 
Aerobic training programs have resulted in improvements in motor (45; 46) and 
cardiorespiratory (97; 102; 108) performance in persons with MS.  Interestingly, 
spasticity is also ameliorated by an acute bout of unloaded leg cycling in persons with 
MS on (73) and off (74) anti-spasticity medication.  Although these studies showed 
cardiovascular benefits, strength and or power gains from aerobic training are not 
always examined.   
Resistance training is traditionally used to improve muscle strength directly, as it 
targets specific muscle groups.  Neural adaptation and muscle hypertrophy are the 
primary mechanisms of muscle strength gains during short- and long-term resistance 
training, respectively (69).  Potential mechanisms of neural adaptation include increased 
motor unit recruitment and rate-coding, better activation of synergist muscles, and 
reduction in co-activation of antagonist muscles (110).   
Few studies have used resistance training programs in persons with MS.  Home-
based (31) and supervised (127) resistance training programs have produced 
improvements in strength, power, and measures of functional mobility (i.e., up-and-go 
test, number of steps within 3 minutes, walking speed).  However, these studies did not 
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 include a non-MS control group, which would have provided information regarding the 
degree of change in strength, power, and functional mobility in persons with MS 
following resistance training.  Thus, it is not clear whether the response to resistance 
training (i.e., changes in strength, neural adaptation, muscle hypertrophy) may be 
blunted by MS.   
The underlying mechanisms of strength and power gains in persons with MS are 
not known.  Because of the pathophysiological nature of MS, it is not clear whether 
neural adaptations from 2 weeks of resistance training can occur in people with MS, nor 
is it clear how the magnitude of these adaptations in persons with MS may compare to 
persons without MS.  In persons with no neurological impairment, increased motor unit 
firing rates (52) and reduction in co-activation of antagonist muscles (49) have been 
observed following resistance training.  It is not known if 2 weeks of resistance training 
will have a beneficial effect on postural control in persons with MS.  If beneficial 
effects are observed, this would imply that neural adaptations are enough to improve 
balance in persons with MS. 
Significance of Dissertation 
Inadequate motor performance is a problem in persons with MS.  The primary 
mechanism of muscle weakness may partially be a compromised central nervous 
system, which may further affect secondary mechanisms (i.e., muscle size, contractile 
function, etc.).  Further, power loss in persons with MS may also be exacerbated by the 
presence of spasticity within the muscle.  The contribution of all of the potential 
mechanisms of muscle weakness is not clear, and an understanding of these 
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 mechanisms of weakness will be useful in designing appropriate therapeutic 
interventions to improve muscle strength and power in persons with MS.   
Muscle weakness may partially explain the limitations in performing functional 
tasks and maintaining postural control.  Indeed, strength and power gains may place 
persons with MS further away from disability, so that normal daily activities can be 
performed and overall quality of life improved.  However, it is not known if the 
resistance training response in persons with MS is blunted compared to persons without 
MS.  This dissertation would provide some evidence with regard to the reversibility of 
the detrimental effects of MS using short-term resistance training.  Further, benefits of 
resistance training may translate to greater postural control in persons with MS, 
indicating the importance of neural adaptations on balance. 
Study 1:  Mechanisms of Muscle Weakness in Persons with MS 
The primary aim of this study is to determine the mechanisms of diminished 
strength and power in persons with MS.  Lower strength in persons with MS may be 
attributed to muscle atrophy and lower motor unit firing rates.  Spasticity and slow 
contractile function may also be important in lower power in persons with MS.  An 
exploratory aim will examine the contribution of each of the mechanisms of force 
production in explaining muscle weakness.  The knee extensors (KE) will be examined 
in this study, as these muscles are observed to be weak in persons with MS (3; 63; 99; 
111; 121) and are important in activities of daily living24 (15; 21). 
Hypothesis 1.1  Maximal voluntary isometric contraction (MVIC) and peak 
power (highest power in the power-velocity relationship) of the KE will be lower in 
                                                 
24 activities of daily living – such as stair climbing, rising from a chair, walking, etc. 
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 persons with MS compared to non-MS controls, indicating muscle weakness in persons 
with MS. 
Hypothesis 1.2  Motor unit firing rates (needle electromyography; pulses·s-1) of 
the vastus lateralis muscle at 50% and 100% MVIC will be lower in persons with MS 
than non-MS individuals, suggesting that lower central drive to the muscle may 
contribute to strength and power loss. 
Hypothesis 1.3  The ratio of voluntary-to-stimulated rate of force development 
(% peak torque·ms-1) during an MVIC and specific strength (N·m per cm2) will be 
lower in persons with MS compared to non-MS controls, indicating lower 
neuromuscular drive to the muscle in persons with MS. 
Hypothesis 1.4  Muscle cross-sectional area (from magnetic resonance imaging; 
cm2) of the KE will be smaller in persons with MS than non-MS controls, suggesting 
that a reduction in muscle size may contribute to strength and power loss. 
Hypothesis 1.5  The rate of force development from a stimulated tetanus (% 
peak force·ms-1) will be lower in persons with MS than non-MS individuals, suggesting 
that contractile function or excitation-contraction coupling may contribute to power 
loss. 
Hypothesis 1.5  The ratio between passive torque from the hamstrings and 
voluntary torque from the KE at high velocities (>120°·s-1) will be greater in persons 
with MS than non-MS individuals, suggesting that spasticity contributes to reduced 
power during high velocity contractions via co-activation of the antagonist muscle.  
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 Study 2:  Resistance Training in Persons with MS 
Aim #1 
The primary aim of this study is to determine the effects of 2 weeks of high-
intensity resistance training (3 times per week) on muscle strength and power, motor 
unit discharge rates, and antagonist muscle co-activation in persons with and without 
MS.  In persons without MS (C), strength gains during short-term training are primarily 
due to neural adaptations and not due to muscle hypertrophy (69).  As MS is a central 
nervous system disease, it may be that neural adaptations (i.e., increased motor unit 
discharge rates and lower co-activation of antagonist muscles) are blunted during short-
term resistance training compared to persons without MS.  The KE will be examined in 
this study. 
Hypothesis 1:  Increases in KE strength (maximal voluntary isometric 
contraction, MVIC; % pre-training) and power (% pre-training) will be greater in C 
compared to MS following 2 weeks of resistance training, indicating a blunted response 
to resistance training in people with MS. 
Hypothesis 2:  Maximal motor unit firing rates (pulses·s-1) of the vastus lateralis 
muscle during contractions at 100% MVIC will increase in both C and MS following 2 
weeks of resistance training, indicating that neural adaptations occurred during 
resistance training. 
Hypothesis 3:  The change in maximal motor unit firing rates of the vastus 
lateralis muscle at 100% MVIC following 2 weeks of resistance training will be smaller 
in MS compared to C, suggesting blunted responses in motor unit behavior in persons 
with MS. 
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 Hypothesis 4:  Co-activation (%) will be lower in both MS and C following 2 
weeks of resistance training compared to pre-training levels, suggesting more effective 
coordination of neural activation during contractions following training.  
Exploratory regression analyses will also be conducted to examine the extent to which 
neural adaptations explain changes in strength and power, as well as how strength and 
power improvements affect physical function.  These results will provide evidence that 
short-term resistance training can increase muscle strength and power, as well as show 
that the nervous system of persons with MS has the capacity to improve with resistance 
training. 
Aim #2 
The secondary aim of this study is to investigate the effect of resistance training 
on postural control during 30 s of quiet and leaning (front, back, left, right) stances and 
physical function in persons with MS.  Modest, non-significant decreases in postural 
sway were reported in persons with MS following a home-based resistance training 
program (31).  During leaning stances in different directions, limits of stability 
increased in persons with no neurological impairment following resistance training 
(109).  Better balance may translate to improve physical functioning.  Since persons 
without MS have minimal balance problems and have adequate functional mobility, 
changes in postural control and physical function may be greater in MS compared to C. 
Hypothesis 2.2.1  The net center of pressure variability (mm) and time-to-
contact (s) during 30-second trials of quiet and maximal leaning (front, back, left, right) 
will decrease in both C and MS following 2 weeks of resistance training, suggesting 
improvements in postural control. 
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 Hypothesis 2.2.2  The change in net center of pressure variability and time-to-
contact during quiet and maximal leaning (front, back left, right) stances will be greater 
in MS compared to C, suggesting greater postural control improvements in persons 
with MS compared to non-MS controls following 2 weeks of resistance training. 
Hypothesis 2.2.3  The change in 10s rapid foot-tap count, timed 10m walk, 
timed up-and-go test, and timed chair rises will be greater in MS compared to C, 
suggesting physical function improvements in persons with MS compared to non-MS 
controls following 2 weeks of resistance training. 
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 Figure 1.1  
Muscle spindles detect changes in muscle length and velocity.  When activated, a 
muscle spindle (A) sends an impulse along the Ia afferent nerve (blue) and makes 
synaptic connections with the Ia efferent nerve of the agonist muscle (red) and the Ia 
inhibitory interneuron (green), which will make synaptic connections with the Ia 
efferent nerve of the antagonist muscle (purple).  Simply, the stretch reflex excites the 
agonist muscle of which the muscle spindle resides and inhibits the antagonist muscle.  
Adapted from Human Anatomy and Physiology, Marieb 7th edition. 
A
Copyright © 2006 Pearson Education, Inc., Publishing as Benjamin 
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 CHAPTER 2 
LITERATURE REVIEW 
Introduction 
Muscle weakness is a common problem in MS (National Multiple Sclerosis 
Society), and alterations in the physiological processes that underlie voluntary force 
production may explain lower strength in persons with MS.  Central processes25 that are 
directly affected by the pathophysiology of MS may be the predominating mechanisms 
of muscle weakness, which in turn may affect peripheral mediators of force 
production26 and muscle size.  Spasticity27, another common problem in MS, may also 
decrease power through antagonist coactivation of spastic muscles (22).  It is not clear 
what the major contributors of muscle weakness are in persons with MS. 
Muscle weakness may play a role in reduced postural control and physical 
function in persons with MS.  Short-term resistance training of lower extremity muscles 
may provide a means for improving postural control via neural adaptation in persons 
with MS.  Neural adaptation is shown to contribute to early strength improvements (2 
weeks) during a resistance-training program in young adults without MS (69).  
However, it is not clear whether neural adaptation is blunted in persons with MS 
because of the pathophysiology.  In addition, it is unknown whether short-term 
resistance training can improve postural control in persons with MS.  The aim of this 
                                                 
25 central processes – such as motor unit firing rates, motor unit recruitment, conduction of neural 
impulse 
26 peripheral mediators of force production – such as neurotransmitter release at the neuromuscular 
junction, muscle membrane excitability, propagation of neural impulse along the sarcolemma, calcium 
release from the sarcoplasmic reticulum, cross-bridge cycling 
27 spasticity - characterized as a velocity-dependent resistance to passive stretch by the antagonist muscle 
due to the hyperexcitability of the stretch reflex (64) 
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 chapter is to present existing literature on potential mechanisms of muscle weakness, 
functional mobility, postural control, and resistance training in persons with MS.   
Sources of muscle weakness in persons with MS 
Central Nervous System 
The integrity of myelin sheaths, which insulate neurons of the central nervous 
system, is crucial in ensuring adequate delivery of central impulses to effector organs.  
Myelin sheaths are layers of phospholipid proteins that surround neuronal axons to 
promote quick transmission of action potentials along the nerve via saltatory 
conduction.  Also, myelin sheaths are dielectric28, preventing the electrical current from 
leaving the axon – much like the rubber insulation surrounding a copper wire.   
A hallmark of MS is the demyelination of neurons.  Demyelination affects the 
central transmission of afferent (sensory) and efferent (motor) impulses.  Conduction 
blocks may arise and signal transmission failure may occur due to a reduction in the 
safety factor29 for impulse transmission in demyelinated and lesioned neurons (62; 84).  
Clinically, a marked reduction in the amplitude or area of an evoked action potential 
may indicate the presence of a conduction block in patients with neuropathological 
diseases (23).  Axonal damage in demyelinated areas of the neuron has been observed 
in persons with MS, using magnetic resonance imaging and magnetic resonance 
spectroscopic imaging (78).  If severe axonal damage leads to Wallerian degeneration, a 
decrease in motor unit size and number may occur, which in turn may decrease force 
production.  However, no studies have examined motor unit size and number in persons 
with MS. 
                                                 
28 dielectric – non-conducting 
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 Central activation of the muscle plays a key role in voluntary force production.  
Voluntary movements are initiated at the motor cortex through the transmission of 
impulses along efferent pathways that recruit motor units.  The central regulation of 
muscle force primarily involves the rate at which central impulses excite the muscle 
(i.e., motor unit firing rate, MUFR) and the recruitment of motor units.  Intramuscular 
electromyography (EMG) is a technique used to record individual motor unit firings via 
a needle electrode within the muscle.  Compared to non-MS controls, motor unit firing 
rates are lower (33; 106) and highly variable (33) in persons with MS.  In contrast, the 
magnitude of surface EMG activity during force production from 10% to 70% of MVC 
is greater in persons with MS compared to non-MS controls (83).  It has been suggested 
that the increased EMG activity may be due to greater motor unit recruitment as a 
compensatory mechanism to overcome lower motor unit discharge rates in persons with 
MS (83).  Although indirect evidence suggests alterations in motor unit recruitment in 
persons with MS, no direct measures of recruitment thresholds have been conducted in 
this population. 
Transcranial magnetic stimulation is used to examine the transmission of these 
impulses by recording the corticomotoneuron conduction time30, as well as the 
amplitude and area of the impulse that reaches the muscle (motor evoked potential, 
MEP).  Studies using transcranial magnetic stimulation of the brain show prolonged 
corticomotoneuron conduction time (43; 123) and lower MEP amplitude and area (43) 
in persons with MS compared to non-MS controls.  Abnormalities in MEP amplitude 
and area are shown to be more frequent in MS patients with higher disability (Expanded 
                                                                                                                                               
29 safety factor – the difference between the threshold and peak amplitude of an action potential 
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 Disability Status Scale score 2-3.5 versus 0-1.5) (43).  Bonfiglio et al. (12) 
demonstrated that the cortical relay of impulses within the cerebrum may be altered in 
persons with MS, in that the prolonged delay in conduction time is primarily due to 
alterations in transcortical transmission rather than either afferent and efferent nerve 
transmission.  The cortical relay time was unrelated to the disease duration of MS (12).  
Prolonged absolute and relative refractory periods are also observed in MS patients 
(10).  Together, these studies suggest that impaired central activation via prolonged 
delivery and reduced amplitude of impulses may affect excitation of motor units and 
may partially explain reduced force production in persons with MS.   
The level of central activation to the muscle can also be examined non-
invasively at the periphery by using the following methodologies: central activation 
ratio, specific strength, and rate of voluntary force production.  Central activation ratio 
is the maximal voluntary force relative to the total force produced during the 
superimposition of an electrical stimulus or train of stimuli during a maximal voluntary 
contraction (MVC) (55).  Central activation failure can be determined by observing an 
increment in force during the superimposed stimuli on the MVC.  Specific strength is 
the force per muscle cross-sectional area and allows the determination of muscle 
quality, independent of muscle size.  Rate of voluntary force development during a 
MVC is expressed as the percent change in peak force over time and provides some 
indication of neuromuscular drive and contractile properties.   
Lower central activation ratio (28; 82; 113) and rate of force development (82) 
are observed in persons with MS compared to non-MS controls.  There is a modest 
                                                                                                                                               
30 corticomotoneuron conduction time – the time it takes the impulse to travel from the motor cortex to 
the muscle 
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 decrease in specific strength of the ankle dorsiflexors in persons with MS compared to 
non-MS controls (82), but this is not always observed (57).  In rats infected with 
experimental allergic encephalomyelitis31, specific strength of the medial gastrocnemius 
is lower compared to controls (29).  Interestingly, lower specific tension32 in type I 
fibers is observed in persons with MS, suggesting that there may be alterations at the 
myofilament level (44).  The inconsistent results of specific strength may be a result of 
greater variability of specific strength among persons with MS compared to non-MS 
controls.  It may be that declines in specific strength are more evident in other muscle 
groups. 
In summary, the pathophysiology of MS has an impact on central factors that 
influence the activation of skeletal muscle.  Central regulation of force production, 
amplitude and area of action potentials, and corticomotoneuron conduction time appear 
to be altered in persons with MS compared to non-MS controls.  Thus, these changes in 
the central nervous system may partially explain muscle weakness in persons with MS. 
Neuromuscular Transmission 
Neuromuscular transmission involves the translation of a neural signal to a 
neurotransmitter signal, which in turn translates into an electrical signal at the muscle.  
Specifically, an action potential at the axon terminal causes the release of acetylcholine 
that crosses the synaptic cleft and binds to receptors at the motor end plate.  This causes 
depolarization of the muscle membrane, and if depolarization reaches a threshold, it will 
generate an action potential that will propagate along the sarcolemma and into the 
                                                 
31 experimental allergic encephalomyelitis – animal model for multiple sclerosis 
32 specific tension – force produced by a single muscle fiber 
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 transverse-tubules.  Failure in any of the aforementioned events could inhibit force 
production. 
Amplitude of evoked potentials at the ulnar nerve during a short train of stimuli 
is lower in MS patients compared to non-MS controls (94), indicating some alteration in 
neuromuscular transmission.  Evoked potential amplitudes following administration of 
anticholinesterase therapy, which minimizes the breakdown of acetylcholine in the 
synaptic cleft, are improved in persons with MS (94), suggesting that neurotransmitter 
release or its effect on receptors is impaired.  Following local treatment of curare33, 
recovery of evoked potential amplitudes is slower in people with MS compared to 
controls (34), signifying that impairments in neuromuscular transmission may be due to 
alterations at the receptor level of the motor end plate.  However, persons with MS with 
spasticity show minimal depression of the H-reflex response following a slow stretch of 
the soleus muscle, as well as greater facilitation of the soleus H-reflex response 
compared to controls, indicating decreased presynaptic inhibition (85).  Collectively, 
these studies show that neuromuscular transmission is changed in persons with MS and 
could affect force production. 
Muscle Size  
Muscle size is important in strength and power production.  Both number and 
area of muscle fibers contribute to overall force production.  Declines in whole muscle 
(57) and single muscle fiber (44; 57) cross-sectional area (CSA) are observed in persons 
with MS.  However, size differences at the whole muscle (82) and fiber level (16) are 
not always observed in persons with MS.  These discrepancies may be explained by 
                                                 
33 curare - temporarily blocks nicotinic acetylcholine receptors on the motor end plate 
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 increased data variability in persons with MS, which may be, in part, due to different 
degrees of disability and physical activity levels.   
The distribution of slow- and fast-twitch fibers may play a role in the velocity 
component of power production, as fast-twitch fibers have greater shortening velocity 
than slow-twitch fibers.  Using the myosin ATPase staining technique, a higher 
percentage of type IIa fibers and a lower percentage of type I fibers in the tibialis 
anterior muscles were observed in MS patients compared to controls (57).  In contrast, 
when fiber type distribution is determined by gel electrophoresis and silver-staining 
techniques, MS patients had a lower distribution of type IIa myosin heavy chain (MHC) 
isoform (44) and greater distribution of type I/IIa/IIx MHC isoforms in MS (16) in the 
vastus lateralis muscle.  These discrepant results may be due to the different muscles 
studied and the analytical approaches used in identifying fiber types.  Nevertheless, 
there appears to be a shift towards slow-twitch fibers, as well as a greater percentage of 
hybrid fibers in persons with MS.  
The unloaded shortening velocity of type I and type IIa fibers (44) and the 
myosin ATPase activity for each fiber type (17) were similar between persons with MS 
and non-MS controls.  These data suggest that the rate of cross-bridge cycling is 
unaltered in persons with MS.  Interestingly, Garner et al. (44) found that specific 
tension was lower in type I, but not type IIa, fibers in persons with MS, suggesting that 
there may be an alteration in the number of cross-bridges or force per cross-bridge in 
type I fibers.   
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 Contractile Function 
Contractile function during voluntary contractions is influenced by central34 and 
peripheral35 factors.  As described earlier, changes in central activation occur in persons 
with MS, and these central changes may bring on a cascade of changes within the 
muscle.  Some studies examining contractile function in the periphery indicate lower 
rates of force development (113) and slowed force relaxation (82; 113) during 
electrically stimulated contractions in persons with MS, while other studies do not (28; 
30).  There is a leftward shift in the torque-velocity relationship in lower extremity 
muscles (82) but not in upper extremity muscles (30) in persons with MS compared to 
non-MS controls, suggesting a slower muscle profile in muscles that work against 
gravity.   
Contractile velocity, important in power36 production, may be altered in persons 
with MS.  Spasticity, a common symptom in MS, may impede high contractile velocity 
due to the hyperexcitability of the stretch reflex (see Spasticity).  At the muscle fiber 
level, spastic muscles have shorter fiber lengths compared to non-spastic muscles (41), 
signifying a lower number of sarcomeres in series, which would affect contractile 
velocity.  Increased muscle stiffness37 is also observed at the whole muscle (114) and 
muscle fiber (41) levels.  Thus, muscle stiffness may play a role in lower power 
production due to the increased difficulty to generate fast contractile velocities. 
                                                 
34 central – i.e., motor unit discharge rates 
35 peripheral – i.e., fiber-type distribution, calcium kinetics, fiber length (number of sarcomeres in 
series) 
36 power – product of torque and velocity 
37 stiffness - resistance to passive movement that may be due to non-reflex mechanisms 
 25
 Spasticity 
Spasticity is defined as a “motor disorder characterized by a velocity-dependent 
increase in tonic stretch reflexes (muscle tone) due to the hyperexcitability of the stretch 
reflex, as one component of the upper motor neuron syndrome” (64).  The stretch reflex 
arc encompasses the muscle spindle, the afferent nerve to the spinal cord, and the 
disynaptic connections to the Ia efferent nerve of the agonist muscle and the Ia 
inhibitory interneuron (which will make a synaptic connection with the Ia efferent nerve 
of the antagonist muscle).  Simply, the stretch reflex excites the agonist muscle (the 
muscle that is being stretched) while inhibiting the antagonist muscle.  The mechanism 
of spasticity is still debated, but the hyperexcitability of the stretch reflex may be due to 
dis-inhibition at the presynapse (e.g., diminished neurotransmitter release to the Ia 
motor neuron) and or reduced disynaptic reciprocal Ia inhibition (e.g., lower inhibition 
of the antagonist muscle) (68; 86).   
A common clinical assessment of spasticity is the Ashworth or modified 
Ashworth scale (11).  In these techniques, clinicians manually move the limb segments 
and make judgments based on how resistant the joint movement is.  The subjective 
nature of these tests relies heavily on clinical experience.  And it is difficult to discern 
what is mediating increased passive resistance, structural (non-reflex) or neural (reflex) 
alterations.   
Quantitative methods using biomechanical and or electrophysiological 
instruments have been developed to improve measures of spasticity in patients.  Passive 
torque (dynamometer), oscillation decay (pendulum test), H-reflex, and stretch reflex 
are used as indices of muscle spasticity (9).  Passive torque is the torque produced by a 
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 muscle that is passively stretched by the dynamometer.  The pendulum test uses a 
goniometer to measure oscillation decay of the knee joint when the relaxed leg is 
released from full extension and is allowed to swing freely.  The H-reflex is a surrogate 
measure of motor neuron excitability.  By electrically-stimulating the nerve, the 
maximal amplitude of the H-wave can be determined using surface electromyography 
(EMG).  The stretch reflex is the EMG signal obtained in response to the stretching of 
the muscle.  Although there are many ways to quantitatively measure spasticity, there is 
no gold standard.  The combination of biomechanical and electrophysiological 
measurements may provide a more complete evaluation of spasticity by examining the 
relationship between stretch velocity and passive torque, and the stretch reflex 
threshold, respectively (9).   
Numerous studies have used a quantitative approach to assess muscle spasticity 
in stroke (4; 98) and spinal cord injury patients (37; 51; 76; 96; 100).  Likewise, several 
studies have measured spasticity quantitatively in persons with MS (8; 87; 88; 90).  
Increased passive torque with increasing speed of passive movement (90) and 
dampened oscillation decay (8) at the knee joint are observed in persons with MS.  
Increased stretch reflex amplitude with increasing velocity and lower stretch reflex 
threshold (i.e., the velocity at which passive torque is detected) of the soleus are 
observed in MS patients (87; 88).   
Coactivation of the antagonist muscle, as a result of spasticity, during a 
voluntary dynamic contraction, may impede power production of the agonist muscle.  
Corcos et al. (22) showed a stretch reflex-induced coactivation of the soleus during 
dorsiflexion in spastic patients.  Musampa et al. (75) also observed stretch reflex-
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 induced coactivation of the stretched muscle during elbow extension in stroke patients.  
It remains unclear if stretch reflex-induced coactivation plays a role in lower force 
production in persons with MS, particularly during high velocity contractions. 
Summary:  Sources of muscle weakness in persons with MS 
Overall, there are many factors that may explain muscle weakness in persons 
with MS.  These include neural alterations at the central and peripheral levels, changes 
in contractile function, muscle atrophy, changes in fiber-type distribution, spasticity, 
and coactivation.  However, the contribution of each of these factors to muscle strength 
and power in persons with MS is not well understood.   
Physical Function and Postural Stability in MS 
Postural control 
Studies have shown that postural control in MS is compromised.  Persons with 
MS exhibit reduced anterior and posterior center of pressure displacements when 
leaning compared to non-MS controls (53).  Women with MS have greater center of 
pressure variability in the AP direction and greater load asymmetry38 during quiet 
stance compared to non-MS women (21).  When one or more sensory systems (visual, 
somatosensory, vestibular, proprioception) are perturbed, persons with MS demonstrate 
greater postural sway (79).  Postural sway velocities in the AP and ML directions 
during quiet stance on stable and foam rubber support surfaces are greater in persons 
with MS compared to non-MS controls (47). 
Postural control may be better measured by time-to-contact, which provides 
temporal and spatial information about center of mass relative to the stability boundary, 
                                                 
38 load asymmetry – differences in the ground reaction forces between feet 
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 than spatial measurements, e.g., center of pressure variability.  However, time-to-
contact has not been measured in persons with MS.  In studies of aging, older adults 
exhibit lower time-to-contact in the AP (39; 124) and ML (124) directions during 
leaning tasks compared to younger adults.  In Parkinson’s Disease patients, time-to-
contact in the ML direction is lower compared to healthy controls (125).  Time-to-
contact may be useful in achieving a comprehensive description of postural control in 
persons with MS. 
Gait 
Physical function and postural stability are important in maintaining activities of 
daily living.  Persons with MS have slower gait speeds (16; 21; 67; 70; 91; 111; 121), 
consisting of shorter stride lengths, decreased cadence, and prolonged double-support 
phase during the gait cycle (7; 67).  Further, joint angles during the gait cycle are also 
altered in minimally-impaired persons with MS (7; 67).  Olgiati et al. (93) showed high 
energy costs of walking on a treadmill in persons with MS compared to non-MS 
controls, which was associated with knee flexion-extension time (their spasticity 
measure) in MS patients (91).   
In addition to slow walking speeds, women with MS have greater difficulty 
initiating gait (104).  Minimal displacement of the center of mass (due to a slow anterior 
velocity in the anticipatory postural adjustment) and smaller posterior shift in the center 
of pressure during gait initiation were observed in women with MS compared to non-
MS controls.  These data suggest that persons with MS may have a functional strategy 
to stay within their stability boundaries39 until necessary to make the first step (104).   
                                                 
39 stability boundaries – the perimeter of balance 
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 Effect of muscle strength on postural control and physical function 
Muscle strength is important in postural control, which in turn is necessary for 
the performance of activities of daily living.  Muscle strength and postural control are 
linked in that they share the same descending pathway in the nervous system to activate 
skeletal muscle.  There are very few studies directly examining the role of muscle 
weakness in postural control in persons with MS.  Chung et al. (21) observed a 
correlation between power asymmetry in the knee extensors and center of pressure 
variability in persons with MS.  In stroke patients, Marigold et al. (66) observed 
associations between strength and postural sway when patients had to rely only on their 
vestibular system.  Correlations between muscle strength and postural sway velocity 
during quiet stance are observed in Parkinson’s Disease patients (77).  When strength is 
improved by bilateral resistance training of the knee extensors, middle-aged and older 
adults increased their limits of stability during leaning trials in different directions 
(109).   
Muscle strength also plays an important role in physical function.  Leg power is 
predictive of functional mobility and performance in the elderly (5; 26).  In MS patients, 
gait speed is associated with muscle strength (120), particularly in patients who have 
both pyramidal and sensory impairments (121).  Recently, knee extensor power 
asymmetry was correlated with self-selected, normal and brisk walk times in persons 
with MS and non-MS controls, suggesting that asymmetrical weakness may play a role 
in physical dysfunction in persons with MS (21).   
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 Summary:  Physical function and postural stability in MS 
Overall, physical function and postural control are compromised in persons with 
MS.  Slow walk speeds, altered gait kinematics, and prolonged gait initiation in MS 
patients indicate a functional strategy to minimize the risk of falls.  Greater postural 
sway in persons with MS suggests difficulties in maintaining balance control.  The 
inclusion of time-to-contact may give a better description of postural control changes in 
persons with MS, as it includes both spatial and temporal components of postural 
control.  The relationship between muscle strength and postural control needs further 
investigation in persons with MS.  It is not clear whether strength gains from resistance 
training would improve postural control in persons with MS. 
Effect of resistance training on motor performance in MS 
Resistance training is an effective way of improving strength and power in 
targeted muscle groups.  There are a number of systemic changes that contribute to 
strength gains during long-term resistance training.  A classic paper by Moritani and 
DeVries (69) showed both training-induced neural and morphological contributions to 
strength gains in young, healthy adults, each contributing more to increased strength at 
different phases of the resistance training period (Figure 2.1).  Neural adaptations 
contributed about ~80% during early strength gains at week 2.  However, its relative 
contribution declined as muscle hypertrophy’s contribution to strength gains increased 
after 4 weeks of training.  Potential mechanisms of neural adaptation to strength training 
are: 1) complete activation of the prime mover by increased motor unit recruitment and 
firing rates, and 2) appropriate activation of synergist and antagonist muscles (110).  
Motor unit firing rates are increased within the first 2 weeks of resistance training in the 
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 elderly, who had lower motor unit firing rates compared to young adults at baseline 
(52). 
There are limitations to Moritani and DeVries work.  Neural adaptation was 
monitored using integrated, surface EMG signals.  Muscle hypertrophy was measured 
by taking the largest leg circumference.  A better approach would be to measure neural 
adaptation using intramuscular EMG for motor unit firing rates and magnetic resonance 
imaging (MRI) for muscle cross-sectional area.  Nevertheless, Moritani and DeVries 
demonstrated that 2 separate mechanisms (neural and muscular components) contribute 
to strength gains during resistance training.   
There are several studies that have used resistance training in persons with MS.  
DeBolt et al. (31) observed increased leg power (sum of both leg extensors) following 
an 8 week home-based resistance training (3x/wk for 30min) using weighted vests and 
ankle cuffs.  White et al. (127) observed strength gains in the knee extensors and 
plantarflexors, but not in the knee flexor muscles, following an 8 week resistance 
training (2x/wk for 30min) using weight machines (ramp protocol; intensity ranging 
from 50% to ~70% MVC).  Taylor et al. (118) showed increases in arm and leg press 
1RM, following 10 weeks of progressive resistance training (2x/wk for 60min).  In 
addition to strength or power gains, persons with MS had modest-to-moderate 
improvements in physical function, such as decreased time in the up-and-go test (31), 
increased number of steps over a 3 min period (127), muscular endurance (118), and 
improved gait kinematics40 (48).  It is not clear whether these gains in strength and 
power are comparable to non-MS controls, as no non-MS control groups were used in 
                                                 
40 improved gait kinematics – decreased time in the double-support phase and stride length in the gait 
cycle 
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 the above-mentioned studies.  It is unknown whether greater gains in strength and 
power would have been observed if strength and power were measured using the same 
contraction mode as training.  Also, potential mechanisms that may explain for 
increased strength and power were not examined in these studies.   
The underlying mechanisms that contribute to improvements in muscle strength 
and power in persons with MS are not known.  Neural adaptation may occur through 
short-term resistance training and may potentially reverse or slow the detrimental 
effects of MS.  Häkkinen et al. (49) observed a reduction in coactivation of antagonist 
muscles in the elderly to levels of middle-aged controls, following 6 months of 
explosive resistance training.  Thus, resistance training may lessen coactivation in 
persons with MS.  However, neural adaptation may be blunted in persons with MS 
because of the pathophysiology of MS.  Nevertheless, neural adaptations may improve 
physical function and postural control in persons with MS by increasing central 
activation of the muscle and maximizing force generation. 
Summary:  Effect of resistance training on motor performance in MS 
Strength and power gains can be achieved in persons with MS following 
resistance training, however to what extent is unknown.  Neural adaptation may impede 
negative changes in the nervous system due to MS by increasing motor unit discharge 
rates and reducing coactivation.  Neural adaptations may also improve postural control 
in persons with MS, suggesting a cause and effect relationship between neural input and 
postural stability. 
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Figure 2.1.   
 
The contribution of neural adaptation and muscle hypertrophy to strength gains changes 
over time during resistance training.  Neural adaptation plays a greater role in strength 
gains early in resistance training (10 reps of dumbbell exercises at 66% RM using 
elbow flexors, 2x per day, 3x per week for 8 weeks) , whereas muscle hypertrophy 
plays a greater role later in resistance training in young adults.  Adapted from Moritani 
and DeVries (69). 
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 CHAPTER 3 
PROPOSED METHODS FOR STUDY 1 
Participants 
Persons with MS and age- and gender-matched non-MS controls will be 
recruited from the local community.  The inclusion and exclusion criteria are presented 
in Table 3.1.  Group sizes (n=12 in each group) were estimated from various measures 
of interest (see Table 3.2).  Due to the lack of information about passive torque in 
persons with MS, 14 participants in each group will be studied.  This study will be part 
of a larger study, funded by the National Multiple Sclerosis Society RG-3974. 
Experimental Design 
All participants will be screened over the phone prior to their first visit.  Visits 1 
and 2 will be conducted in the Muscle Physiology Laboratory.  During Visit 1, 
participants will read and sign the informed consent document prior to their 
participation in the study.  The following forms will also be completed by the 
participant: self-reported EDSS (14); Fatigue Severity Scale (FSS; (60)), Modified 
Fatigue Impact Scale (MFIS), Spasticity Scale, Medical History Questionnaire, Physical 
Activity Readiness Questionnaire, and Magnetic Resonance Safety Questionnaire.  
Height, mass, and physical function41 will be measured.  Familiarization to Biodex 
procedures will also take place.  Prior to leaving the lab, participants will be given an 
accelerometer (GT1M, Actigraph Inc., Pensacola, FL) to wear around their waist for 7 
days during waking hours.  An activity log will also be provided for participants to 
record their daily activities.  Accelerometry will be used to match physical activity 
                                                 
41 physical function – measures include 10 s rapid foot-tapping, 10m timed walk at brisk and usual 
speeds, timed up-and-go test, timed chair rises (x5) 
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 levels between MS and non-MS groups, to prevent potential confounding results due to 
differences in physical activity. 
In Visit 2, participants will perform the Passive Torque, Isometric Contraction, 
Dynamic Contraction, and Electrical Stimulation Protocols.  In Visit 3, participants will 
perform the Intramuscular Electromyography Protocol in the Exercise Neuroscience 
Laboratory.  Visits 2 and 3 will be separated by 7 days to ensure adequate rest and to 
avoid muscular fatigue.  The order of which leg is studied first will be randomized and 
balanced across groups.  To minimize symptomatic fatigue in persons with MS, the 
laboratories will be air-conditioned.  Visit 4 will take place in the Magnetic Resonance 
Imaging (MRI) Center at Cooley Dickinson Hospital, where the participant’s thigh 
muscles will be imaged.  Table 3.3 summarizes the participant’s schedule for Study 1. 
Biodex Isokinetic Dynamometer 
Following a 3 minute warm up on a recumbent cycle ergometer (Schwinn 210p; 
at no resistance), participants will be seated on the Biodex dynamometer (Biodex 
Medical, Shirley, NY, U.S.A.) with the hip angle set at ~90º.  The knee joint will be 
aligned with the axis of the dynamometer arm.  Velcro straps will be used to secure the 
leg to the dynamometer arm.  Shoulder, waist, and thigh straps will be used to stabilize 
the body and leg.  Although the KE are the primary muscle groups of interest in this 
study, the knee flexors (KF) will also be tested for normalization of EMG responses.  
For isometric contractions, the knee angle will be fixed at 90º flexion42 for knee 
extension and knee flexion.  In addition, the knee will be fixed at the optimal angle for 
knee extension and knee flexion (80º and 40º flexion, respectively) to measure maximal 
                                                 
42 90° knee flexion – relative to full extension (0 degrees) 
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 force production and maximal EMG activity.  For passive and voluntary dynamic knee 
extension, the total range of motion (ROM) will be 70°, starting at 90° flexion.  Verbal 
encouragement will be provided for all contractions.  Torque, velocity, position, and 
EMG signals will be sampled at 1000 Hz using a customized data acquisition program 
in MATLAB software (MathWorks Inc., Natick, MA, U.S.A.).  Two surface, bipolar 
electromyography (EMG) electrodes will be taped onto the skin above the vastus 
lateralis and semimembranosus muscles at sites recommended by Cram et al. (24).  
These muscles were chosen to minimize any potential cross-talk that may occur during 
muscle activity.   
Passive Torque Protocol 
Passive torque (N·m) will be measured in each leg for the following velocities 
obtained in random order and blocked by group: 10, 30, 60, 90, 120, 150, 180, 210, 240, 
270, and 300 °·s-1.  Two continuous cycles of knee extension and flexion will be 
recorded at each velocity with 5 s rest between directions.  The passive torque obtained 
at 10 °·s-1 will serve as “baseline” when comparing torques at other velocities.  This 
comparison will detect any increments in passive torque that occur at higher velocities 
due to greater resistance.  Torque, position, and velocity data will be recorded.  After 
correcting for torques due to the moment of inertia, peak torque over the range of 
motion will serve as the index of spasticity.  Passive-to-voluntary torque ratio during 
knee extension will be calculated at each velocity and will be a measure of the effect of 
spasticity in the KF on voluntary torque production in the KE. 
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 Isometric Contraction Protocol 
Participants will perform 3 maximal voluntary isometric contractions (MVIC, 
N·m; 3-4 s duration) of the KE and KF of each leg, with 2 minutes of rest between 
contractions.  If the highest MVIC trials are not within 10% of one another, then 
additional trials43 will be performed.   
Dynamic Contraction Protocol 
Voluntary torque production of the KE will be measured in each leg.  Two 
consecutive (2-3 s rest between contractions) maximal voluntary contractions will be 
performed at each of the following velocities: 30, 60, 90, 120, 150, 180, 210, 240, 270, 
and 300 °·s-1.  The order of the velocities will be same as the Passive Torque Protocol.  
Participants will be instructed to “contract as hard and fast as possible” prior to each 
contraction.  Further encouragement will be given during the contraction.  Once the end 
of the ROM is achieved after each contraction, the leg will be moved passively back to 
the starting position at a velocity of 60 °·s-1.  Participants will have 2 min of rest 
between velocities.   
Electrical Stimulation Protocol 
The knee angle will be set at 90° flexion.  Before placing the surface electrodes 
over the KE, the skin will be abraded and cleansed with abrasive cream and alcohol, to 
improve the signal-to-noise ratio.  A constant current stimulator (model DS7A, 
Digitimer, Hertfordshire, UK) and two 3” x 5” adhesive pad electrodes, placed at 
proximal and distal ends of the KE, will be used to apply a 80 Hz tetanus.  The 
stimulation intensity will be determined by incrementing the current until 50% of MVIC 
                                                 
43 additional trials – total of 6 trials 
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 is achieved.  Then, 3 tetanic trials will be performed with 2 min of rest between trials.  
This protocol will be conducted on KE of both legs. 
Intramuscular EMG Protocol 
Motor unit firing rates will be collected in the Exercise Neuroscience 
Laboratory.  Participants will be seated upright with hip and knee angle fixed at ~90°.  
A heavy-duty Velcro strap will be wrapped around the waist to stabilize the body.  A 
Velcro strap will be used to secure the ankle to a force transducer (Interface SM-250, 
Scottsdale, AZ). 
Participants will perform 3 MVICs of KE, separated by 2 min, with visual 
feedback of their force production on a computer screen.  If the MVICs are not within 
10% of each other, additional MVICs will be performed.  Then, participants will briefly 
practice achieving 50% MVIC. 
Once peak MVIC is determined, the skin over the knee cap and belly of the 
vastus lateralis will be cleansed with alcohol.  A stainless steel ground electrode will be 
taped to the knee cap.  Then, a sterilized, four-wire needle electrode will be inserted into 
the belly of the vastus lateralis to record intramuscular EMG activity.  This electrode 
consists of a 27-gauge stainless steel cannula, which houses a square array of four 50 
µm-diameter platinum-iridium wires, and provides three recording channels of motor 
unit activity.  The electrodes will be connected to a Dantec Clinical Electromyograph 
(Dantec Counterpoint, Dantec Electronik Medicinsk, Skovlunde, Denmark) where the 
intramuscular EMG signals will be displayed on a digital oscilloscope.  Analog signals 
from the EMG electrodes will be bandpass filtered (1-10 kHz) and amplified (mV/D) in 
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 the Dantec Clinical Electromyograph.  Signals from the Dantec and force transducer 
will be acquired at 25.6 kHz. 
After ensuring the subject’s comfort, the subject will be asked to contract their 
KE at 10 to 30% of MVIC to verify good placement of the needle electrode by viewing 
all 3 channels of motor unit action potentials.  If required, a slight adjustment to the 
location of the electrode will be made to obtain clear recordings of motor unit action 
potentials.  
Prior to contraction, participants will be instructed “to contract as hard as they 
can” until they are cued to relax.  Participants will perform a 5 s MVIC with 2 min of 
rest between trials.  Slight adjustments of the electrode will be performed between trials 
to obtain clear recordings of motor unit action potentials, as well as to sample different 
motor units.  After achieving 3 good trials of clear recordings, participants will be asked 
to perform 50% MVIC (using visual feedback of their force production) for 8-10 s, with 
2 minutes of rest between trials.  Again, small manipulations of the needle electrode 
will be made between recordings, and 3 good trials will be achieved before ending the 
protocol. 
Magnetic Resonance Imaging (MRI) Protocol 
Participants will visit the MRI Center at Cooley Dickinson Hospital.  All 
participants will be screened with a Magnetic Resonance Safety Questionnaire prior to 
entry into the magnet room.  Proton MRI will be performed using a 1.5 Tesla whole-
body system (General Electric Company).  Participants will be supine on a bed, and a 
phase-array coil will be wrapped around the thigh.  The bed will then be moved into the 
bore of the magnet so that the mid-thigh is positioned at the isocenter.  Forty-six T1-
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 weighted serial transverse images will be obtained.  The following parameters will be 
used in acquiring serial images:  256 x 256 matrix, field of view of 300mm, 2 averages, 
and slice thickness of 6mm with no gaps.  Participants will have both legs imaged. 
Data Processing 
All participants will be coded by the investigator prior to data collection.  
Following each participant’s completion of the study, identifiable paperwork will be 
removed from the participant folder.  Unless specified otherwise, all data processing 
will be conducted using custom-designed programs in MATLAB. 
Strength and Power 
All torque data will be corrected for the effects of gravity to account for the 
weight of the limb and apparatus.  The highest MVIC will be used for maximal strength 
and to calculate specific strength (N·m·cm-2).  Power (W) will be calculated as the 
product of torque and velocity.  Peak power will be determined by taking the highest 
power calculated from all velocities.  Torque and power pilot data from a non-MS male 
participant are presented in Figure 3.1. 
Neuromuscular Drive 
Acquired signals of motor unit action potentials will be up-sampled to 51.2 kHz.  
Simultaneously acquired force data will be down-sampled to 50 Hz.  Individual motor 
unit action potentials will be identified using customized spike recognition algorithm 
software, which is an automatic spike detection system that makes use of the discharge 
history and template-matching for identification.  Following auto-identification of 
motor units, manual identification will be performed to resolve superpositioned motor 
units and to correct for mis-identified motor units.  The interpulse interval (s) between 
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 consecutive firings of a given motor unit will be determined and averaged during the 
peak plateau of a MVIC.  The firing rate (pulses per second, pps) of a given motor unit 
will be calculated by taking the inverse of the interpulse interval.  The mean firing rates 
of all motor units per contraction will be calculated44.  The maximum and mean firing 
rates during 50% and 100% MVIC for each participant will be determined.  Pilot data 
from a non-MS male participant are presented in Figure 3.2. 
Specific force will be calculated by normalizing MVIC with muscle cross-
sectional area (mCSA), which will be determined by MRI.  For each cross-sectional 
slice, the signal intensity thresholds will be determined to discriminate contractile from 
non-contractile tissue.  The 3 largest consecutive knee extensor mCSAs will be 
analyzed twice by manually outlining the knee extensors, and then, averaged.  As 
another secondary measure of neuromuscular drive, we will use the ratio of voluntary-
to-stimulated rate of force development. 
Contractile Function 
The rate of force development during a 50 Hz tetanus will be expressed as 
percent of peak force per ms and will be a measure of contractile speed.  In addition, the 
velocity that results in 50% of isometric force will be used to determine changes in 
contractile function, represented by shifts in the voluntary torque-velocity relationship 
in persons with MS compared to non-MS controls.   
Spasticity and Coactivation of Spastic Antagonist Muscles 
Peak passive torque (N.m) will be determined at each velocity following 
moment of inertia correction.  The lowest velocity that produces passive torque and 
                                                 
44 firing rates of all motor units … will be calculated – doublets and interpulse interval> 200 ms will 
not be included in the calculation of motor unit firing rates 
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 EMG activity together will serve as the spasticity threshold.  A linear envelope will be 
applied to the surface EMG data and the area of linear envelope will be used as a 
measure of muscle activity.  The ratio of normalized KF and KE EMG activity will be 
used as a measure of coactivation.  Pilot data of torque and surface EMG during 
voluntary dynamic knee extension from a non-MS male participant are presented in 
Figure 3.3. 
Statistical Analyses 
All statistical analyses will be performed using Statistical Analysis Software 
(SAS Institute Inc., version 8.0, Cary, NC).  To characterize our participants, unpaired t-
tests will be used to detect differences between persons with MS and non-MS controls 
in: age, height, mass, FSS, MFIS, spasticity scale, foot-tap counts, walk times, timed 
up-and-go test, timed chair rises, MVIC, peak power, specific strength, spasticity 
threshold, velocities at 50% MVIC, and total accelerometer counts.  A 2-way repeated 
measures analysis of variance (rmANOVA; group x velocity) will be used to detect 
differences in passive torque between groups over the range of velocities. 
For Hypotheses 1.1 to 1.3, an unpaired t-test will be used to detect group 
differences in muscle cross-sectional area, motor unit firing rates during 50% and 100% 
MVIC, ratio of voluntary-to-stimulated rate of force development, and stimulated rate 
of force development.  For Hypothesis 1.4, a 2-way rmANOVA (group x velocity) will 
be tested on passive-to-voluntary torque ratio to detect differences across groups over a 
range of velocities.  In the case of significant interactions, post hoc analyses (Tukey’s) 
will be performed to determine where differences occur.  To explore which mechanisms 
may explain muscle strength (i.e., mCSA, motor unit firing rates) and power (i.e., 
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 mCSA, motor unit firing rates, passive-to-voluntary torque ratio, contractile properties) 
decrements in persons with MS, multiple linear regression analyses will be performed. 
The level of significance will be set at p ≤ 0.05.  Data will be expressed as mean 
± SD.  Precise p-values and the 95% confidence interval for differences between groups 
will be reported, where appropriate.   
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 Table 3.1.   
Inclusion and exclusion criteria. 
 
Inclusion criteria for 
all persons with MS 
 Clinically verified MS 
 Self-reported Expanded Disability Status Score (EDSS) 
between 2 and 6 
 No exacerbations in the past 6 months 
Inclusion criteria for 
all participants 
 Are between the ages of 21 and 60 years 
 Are sedentary to recreationally-active 
Exclusion criteria for 
all participants 
 Have a metabolic, non-MS neurologic, cardiovascular, or 
other disease 
 Taking any medications (other than for MS) that may 
affect muscle function  
 Are pregnant 
 Have a cognitive impairment or a mental disorder that 
precludes following protocol instructions 
 Have arthritis in the lower extremities 
 Have a history of dyspnea, cramping, or light-headedness 
during exercise 
 Are currently smokers or stopped smoking within the past 
6 months 
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 Table 3.2.   
 
Sample size estimates were calculated using unpaired t-tests (power set at 80% and 
significance level set at 0.05) on variables of interest in Study 1.  SD = standard 
deviation.  KE = knee extensors.  VL = vastus lateralis.  DF = dorsiflexors.  MVIC = 
maximal voluntary isometric contraction.  AP COP = center of pressure in the anterior-
posterior direction.  MUFR = motor unit firing rates.  mCSA = muscle cross-sectional 
area.  RFD = rate of force development.  T1/2 = half-time of force relaxation. 
Ref. Variable Mean of 
Non-MS 
Mean 
of MS 
Mean 
of other 
SD Sample size 
estimate 
(121) KE MVIC (N·m) 156  92  38 7 
(21) KE power (W) 206 155  42 12 
 AP COP variability (mm) 4.33 7.52  1.79 7 
(37) Passive KE torque at 120 
°/s (N·m) 
27.9  38.8 
(stroke) 
8.4 11 
(106) VL MUFR (pps) 23.8 13.1  2.6 4 
(57) DF mCSA (cm2) 11.1 7.8  1.2 4 
(113) RFD (% peak force·ms-1) 1017 846  50 3 
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 Table 3.3.   
 
Summary of participant’s schedule for Study 1. 
 
Visit Location Description Approximate 
Duration 
1 Muscle Physiology 
Lab – UMass 
Paperwork, physical function 
assessments, Biodex 
Familiarization, accelerometry 
2 hrs 
2 Muscle Physiology 
Lab – UMass  
Contraction and Electrical 
Stimulation protocols 
2.5 hrs 
3 Exercise 
Neuroscience Lab – 
UMass  
Intramuscular Electromyography 1.5 hrs 
4 MRI Center – Cooley 
Dickinson Hospital 
MRI of thigh muscles 1.25 hrs 
 
 47
  48
Figure 3.1.   
 
Torque (top) and power (bottom) data from a non-MS male participant across a range of 
velocities. 
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 Figure 3.2.   
 
Pilot data of the mean and maximum motor unit firing rates at 50% and 100% MVIC 
from a non-MS male participant. 
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 Figure 3.3.   
Torque and surface EMG of the VL and SM of 3 consecutive dynamic contractions at 
120 °·s-1 (top) from a non-MS male participant.  VL = vastus lateralis.  SM = 
semimembranosus. 
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 CHAPTER 4 
PROPOSED METHODS FOR STUDY 2 
Participants  
Sample size estimates were determined from DeBolt et al. (31) and Christie and 
Kamen (19), which suggested 13 and 10 participants in each group, respectively, to 
detect differences in muscle power and motor unit firing rates pre-to-post training at 
80% statistical power.  Therefore, 10 participants with and 10 without MS will be 
recruited from Study 1 and from the local community.  All participants will undergo 
resistance training in the Muscle Physiology Laboratory.  Study 2 will also be a part of 
a larger study, funded by the National Multiple Sclerosis Society RG-3974. 
Experimental Design 
Table 4.1 summarizes the study timeline for each participant.  Participants will 
come to the laboratories (Muscle Physiology and Exercise Neuroscience Labs) for a 
total of 10 visits:  a familiarization visit, 2 pre-training visits, 6 resistance training 
sessions and 1 post-training visit.  With the exception of the intramuscular EMG 
protocol, which will be conducted in the Exercise Neuroscience Lab, all procedures will 
be performed in the Muscle Physiology Lab. 
During Visit 1, participants will read and sign the informed consent document 
prior to their participation in the study.  Once consent is given, all participants will fill 
out the Medical History questionnaire, Physical Activity Readiness questionnaire, 
Fatigue Severity Scale (FSS), and Modified Fatigue Impact Scale (MFIS).  Persons with 
MS will also fill out the self-reported EDSS.  Height, body mass, and blood pressure 
will be measured.  To evaluate physical function, participants will perform 10 s of rapid 
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 foot-tapping, 10 m timed walk at a brisk and usual paces, timed up-and-go test (8 ft), 
and 5 timed chair rises.  At the end of Visit 1, participants will become familiar with the 
isometric and dynamic contraction protocols on the Biodex isokinetic dynamometer 
(Biodex Medical, Shirley, NY, U.S.A.) on both legs, which will determine the weaker 
leg that will be used for pre- and post-training measure of intramuscular EMG. 
Visit 2 will involve isometric and dynamic contractions with bipolar EMG 
electrodes taped over the vastus lateralis and semimembranosus muscles.  Visit 3 will 
consist of postural control measures and intramuscular EMG.  Resistance training will 
begin the day after the pre-training measures (Visits 4-9).  The first set of maximal 
repetitions on the last training visit (Visit 9) will be replaced with the dynamic 
contraction protocol, to re-assess the load-power relationship.  The day following the 
last training session (Visit 10), postural control measures and intramuscular EMG will 
be re-assessed.  In addition, participants will perform the same physical function 
measures as in Visit 1, to determine whether increases in strength and power are 
associated with improved physical function.  Visits 1 and 2 will be separated by 3 to 7 
days to ensure adequate rest prior to pre-training measures.   
Biodex Isokinetic Dynamometer 
Following a 3-min warm-up on a recumbent cycle ergometer with no resistance 
(Schwinn 210p, Nautilis, Inc., Vancouver, WA), participants will be seated on the 
Biodex dynamometer with the hip angle set at ~90º.  The knee joint will be aligned with 
the axis of the dynamometer arm, and Velcro straps will be used to secure the weaker 
leg.  Shoulder, waist, and thigh straps will also be used to stabilize the body and leg.  
The procedures for isometric contractions of the KE and KF, dynamic contractions of 
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 the KE, and surface EMG electrode placement over the vastus lateralis and 
semimembranosus muscles will be the same as in Study 1.  Verbal encouragement and 
visual force feedback during contractions will be provided to all participants.  Analog 
signals from the Biodex dynamometer (torque, velocity, position) and EMG electrodes 
(Delsys, Boston, MA) will be converted to digital signals (National Instruments 
Corporation, Austin, TX) and sampled simultaneously at 2500 Hz using a customized 
data acquisition program in MATLAB software (MathWorks Inc., Natick, MA, U.S.A.).   
Isometric Contraction Protocol 
Participants will perform 3 MVICs (N·m; 3-4 s duration) of the KE and KF, 
with 2 min rest between contractions.  If the 2 highest MVIC trials within each muscle 
group are not within 10% of one another, then additional trials (up to 6 MVICs) will be 
performed.   
Dynamic Contraction Protocol 
Voluntary torque production of the KE will be measured in the non-dominant 
leg.  Two consecutive (2-3 s rest between contractions) maximal voluntary dynamic 
contractions (MVDC) will be performed at each of the following loads: 20, 30, 40, 50, 
60, and 70 % MVIC.  These velocities were chosen to evaluate peak power from the 
load-power relationship for each participant.  The order of the velocities will be 
randomized across participants and balanced across groups.  Once the end of the ROM 
is achieved, the leg will be moved passively back to the starting position.  Participants 
will have 2 min of rest between velocities.  The optimal load at which peak power is 
produced will be used as the intensity for resistance training. 
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 Postural Control Protocol 
Retroreflective markers will be placed on the participant’s head, trunk, pelvis, 
arms and legs for the calculation of whole-body center of mass in 3 dimensions.  
Marker triads will also be placed over the upper arms, thighs and calves (Figure 4.1).  
Two adjacent force plates (Advanced Mechanical Technology Inc., Watertown, MA) 
will be used to record ground reaction forces.  Participants will stand with their feet hip-
width apart and each foot placed on its own force plate.  Participants will perform 2 
trials of quiet stances, each lasting for 30 s.  Data will be acquired from a camera 
system (Proreflex MCU 240, Qualysis, Gothenburg, Sweden) using Qualisys Track 
Manager (Qualysis Medical AB, Gothenburg, Sweden).  The analog signals from the 
camera and force plates will be sampled at 240 Hz. 
Intramuscular EMG Protocol 
Maximal motor unit firing rates will be collected in the Exercise Neuroscience 
Lab.  The procedures will be the same as in Study 1.  Only the weaker leg will be 
studied. 
Resistance Training Protocol 
Participants will come to the Muscle Physiology Lab for ~30 min, 3 times per 
week for 2 weeks.  Both legs will be trained to examine how changes in strength and 
power affect physical function after training.  At the start of each session, participants 
will warm up on a recumbent cycle ergometer for 3 minutes.  Then, participants will be 
seated on the Biodex dynamometer and will perform 3 MVICs of the KE, with 2 min of 
rest between trials.  This procedure will allow us to track strength gains during the 
course of the training protocol.  The intensity of resistance training will be set at an 
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 optimal load (% MVIC) at which peak power is produced from the load-power 
relationship.  Participants will perform 3 sets of 10 maximal repetitions at the optimal 
load, with 5 min of rest between sets.  Participants will be instructed to contract their 
muscles rapidly and forcefully against the load imposed by the dynamometer.  Verbal 
encouragement and torque feedback (light diode box) will be given to each participant 
at each training session.  Torque, position, and velocity will be recorded during the 
training sessions. 
Data Processing 
All data processing for torque, power, co-activation, motor unit firing rates will 
be the same as in Study 1.  Visual 3DTM (C-Motion, Inc., Rockville, MD) will be used 
to compute the center of pressure (COP) for each foot from ground reaction forces, as 
well as whole-body center of mass from marker coordinates.  The net center of pressure 
represents the whole body center of pressure, calculated as:   
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where Fz is the ground reaction force, and left and right refers to the left or right force 
plate (130).  The center of pressure variability will be the standard deviation of the net 
center of pressure over a time series in the AP and ML directions. 
Time-to-contact (TtC) of the center of mass in the AP direction will be 
calculated by taking the average of the instantaneous distance and velocity of the whole 
body center of mass with respect to the stability boundary over time: 
)i(V
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=     equation 2 
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 where d(i) is the instantaneous distance from the whole body center of mass to the AP 
stability boundary (defined by the perimeter of the feet) and VCOM(i) is the 
instantaneous velocity of the center of mass in the AP direction (125) (Figure 4.2).  In 
quiet stance, the center of mass would not normally cross the stability boundary.  
Therefore, TtC is the predicted time it would take for the center of mass to reach the 
stability boundary based on its current position and velocity.  Figure 4.3 presents the 
time series of TtC from a non-MS male participant. 
Statistical Analyses 
All analyses will be performed using Statistical Analysis Software (SAS 
Institute Inc., version 8.0, Cary, NC).  Unpaired t-tests will be used to detect differences 
in group characteristics (age, height, body mass, FSS, MFIS, and spasticity scale).  To 
test the hypotheses, 2-way repeated measures ANOVA (group x time) will be used to 
examine the changes from pre- to post-resistance training in:  MVIC, peak power, 
maximal motor unit firing rates, co-activation, net COP variability, TtC, and physical 
function (foot-tap counts, brisk and usual pace walk times, timed up-and-go test, and 
timed chair rises).  If significant interactions are present, post hoc analyses (Tukey’s) 
will be used to determine where significant differences occur.  Linear regression 
analyses will be performed to determine associations between muscle strength, power, 
physical function and postural control.   
The level of significance will be set at P ≤ 0.05.  Data will be expressed as mean 
± SD.  Precise p-values and 95% confidence intervals for differences between groups 
will be reported, where appropriate.   
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 Table 4.1.   
 
Summary of participant’s schedule for Study 2.  Baseline measures will take place in 
Visits 2-3, and post-training testing will take place in Visits 10.  During Visit 9, the first 
set will be replaced with the dynamic contraction protocol with surface EMG, to re-
assess load-power relationship. 
Visit Location Description Approximate 
Duration 
1 Muscle 
Physiology Lab  
Paperwork, physical function 
assessments, Biodex familiarization 
1.5 hrs 
2 Muscle 
Physiology Lab  
Isometric and Dynamic Contraction 
protocols plus surface EMG on both 
legs 
2.5 hrs 
3 Motor Control 
Lab  
Postural Control protocol 1.25 hrs 
3 Exercise 
Neuroscience Lab 
Intramuscular EMG of vastus 
lateralis on weaker leg 
1.25 hr 
 
Visits 4-9 
2 weeks of resistance training on both legs 
3x per week 
3 sets of 10 maximal repetitions at optimal load 
 
10 Motor Control 
Lab  
Postural Control protocol 1.25 hrs 
10 Exercise 
Neuroscience Lab 
Intramuscular EMG of vastus 
lateralis on weaker leg 
1.25 hr 
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 Figure 4.1.   
For postural control measures, retroreflective markers will be placed on the head, trunk, 
pelvis, arms, and legs for calculation of whole body center of mass. 
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 Figure 4.2.   
 
Adapted from van Wegen et al. (125), this is a pictorial representation of the time-to-
contact (TtC) measure.  Time-to-contact (TtC) of the center of mass in the AP direction 
will be calculated by taking the average of the instantaneous distance (d) and velocity 
(v) of the whole body center of mass (COM) with respect to the stability boundary 
(solid line around feet) over time. 
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 Figure 4.3.   
 
Time series of TtC during 60 s of quiet stance from a non-MS male participant. 
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 MECHANISMS OF MUSCLE WEAKNESS IN PERSONS WITH MULTIPLE 
SCLEROSIS 
Abstract 
The aim of this study was to identify the key contributors to knee extensor 
muscle weakness in persons with MS.  Lower peak isometric torque (Nm) and power 
(W) were shown in MS (n=14; 12 females, 2 males), compared with age-matched 
control (n=14; 11 females, 3 males).  Smaller fat-free muscle cross-sectional area 
(magnetic resonance imaging, cm2; p=0.04) and lower maximal motor unit discharge 
rates (p=0.04) in the vastus lateralis were observed in MS compared with control.  
Specific strength (Nm·cm-2; p=0.48) was not different across groups, but specific power 
(W·cm-2; p=0.05) was lower in MS.  These results suggest that smaller muscle size and 
lower motor unit discharge rates explain much of the weakness in persons with MS.  
Because muscle size accounted for differences in isometric strength, but not entirely for 
differences in power, the mechanisms of weakness in MS appear to be contraction-
mode specific, and include both anatomical and neural mechanisms. 
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 Introduction 
A common symptom of multiple sclerosis (MS), an auto-immune disease of the 
central nervous system, is muscle weakness.  Lower isometric (18; 80; 82; 83; 111; 113) 
and dynamic (3; 16; 21; 63; 99; 121) torque have been shown in persons with MS 
compared with non-MS controls.  Weakness is particularly evident in the knee extensor 
muscles (3; 18; 21; 63; 99; 111; 121).  Despite numerous studies on isometric strength 
and dynamic power in persons with MS, the mechanisms of MS-related changes in 
force production remain unclear. 
Muscle weakness in MS may be a direct consequence of changes in the central 
nervous system due to demyelination, a defining feature in MS that compromises the 
rapid and complete transmission of action potentials to effector organs, such as skeletal 
muscle.  Investigators have reported central activation failure in persons with MS in the 
ankle dorsiflexor (82; 113) and knee extensor (28) muscles.  Lower maximal motor unit 
discharge rates have been shown in a small group of 4 individuals with MS compared 
with controls during a MVIC (106).  In other neuromuscular disease patients, lower rate 
of force development, normalized to the rate of force development during a stimulated 
contraction, was observed compared with controls (59), suggesting alterations in neural 
drive during voluntary force production. 
Spasticity, another common symptom in MS, may contribute to power deficits 
in this population.  Spasticity is characterized as “a velocity-dependent resistance to 
passive stretch by the antagonist muscle due to the hyperexcitability of the stretch 
reflex” (64).  That is, co-activation of antagonist muscles due to spasticity may slow 
contraction velocity and lower power production of agonist muscles, particularly during 
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 high contraction velocities.  Clinically, spasticity is assessed using the Ashworth or 
Modified Ashworth Scales (11).  Numerous investigators have used biomechanical and 
electrophysiological techniques to quantify spasticity in stroke (4; 98), spinal cord 
injury (37; 51; 76; 96; 100), and MS (8; 88; 90).  Torque resistance to passive limb (i.e., 
passive torque) movement is one measure of spasticity that is obtained using a 
dynamometer.  Nuyens et al. (90) observed higher passive torque during knee extension 
and knee flexion in persons with MS compared with controls.  Spasticity has not been 
measured in the context of its potential effect on muscle weakness in MS.  Thus, it is 
not known whether the degree of spasticity in an antagonist muscle may explain a 
portion of lower torque production of the agonist muscle during dynamic contractions in 
persons with MS.   
Lower fat-free muscle cross-sectional area is observed in persons with MS in the 
ankle dorsiflexor muscles (57).  In addition, studies have shown lower single fiber 
cross-sectional area of ankle dorsiflexor (57) and vastus lateralis (44) muscles in 
persons with MS compared with controls.  Together, these results suggest that smaller 
muscle size is a contributor to muscle weakness in MS.  Investigators have reported a 
modest decline (82) or no difference (57) in specific strength (force normalized to 
muscle size) of the ankle dorsiflexor muscles in individuals with MS compared with 
controls, indicating that muscle quality may or may not be reduced.  To date, no studies 
have examined specific strength and specific power in the knee extensor muscles in 
persons with MS. 
Alterations in contractile function may limit power (a product of contraction 
velocity and torque production), as a slower rate of force development may impede 
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 contraction velocity.  Lower rates of force development during a stimulated contraction 
are observed in the ankle dorsiflexor muscles in persons with MS compared with 
controls (113).  However, others have shown no difference between persons with MS 
and controls in the maximal rate of force development in the knee extensor muscles (28; 
30).  Thus, it is not clear whether lower power may be partially explained by slower 
contractile properties. 
Indeed, there are a number of potential mechanisms that could contribute to 
muscle weakness in persons with MS.  The extent to which these mechanisms influence 
overall strength and power in persons with MS is not clear.  Further, muscle weakness 
in MS has been associated with lower physical function (21; 121) and symptomatic 
fatigue (21), another significant symptom of MS.  These relationships suggest that 
muscle weakness has a negative impact on activities of daily living and overall quality 
of life in persons with MS. 
The aim of this study was to systematically determine the mechanisms of 
diminished isometric strength and dynamic power in the knee extensor (KE) muscles of 
persons with MS.  We hypothesized that, compared with controls, persons with MS 
would have 1) lower peak isometric torque and power, 2) lower maximal motor unit 
discharge rates in the vastus lateralis muscle, 3) higher passive torque in the knee 
flexors (KF) and higher percentage of KF passive-to-KE voluntary torque during high-
velocity (>120 °·s-1) contractions, 4) slower voluntary rate of force development (RFD), 
5) lower fat-free KE muscle cross-sectional area, 6) lower specific strength and lower 
specific power, and 7) slower stimulated RFD.  In addition, isometric strength and 
power associations with key mechanisms of weakness were explored.  Associations 
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 between isometric strength, power, physical function and symptomatic fatigue were also 
explored. 
Methods 
Study Design 
Participants came in for a total of 4 visits, each separated by 3 to 7 days.  
Detailed information for each measure is described in the following sections.  Briefly, 
Visits 1 and 2 were conducted in the Muscle Physiology Laboratory.  At Visit 1, signed 
informed consent, participant characteristics and measures of symptomatic fatigue were 
collected; and familiarization with the Biodex dynamometer (Biodex Medical, Shirley, 
NY, U.S.A.) procedures was performed.  Isometric strength was measured in each leg to 
determine which was weaker.  At the end of Visit 1, participants were issued an 
accelerometer and instructed in its use.  At Visit 2, physical function, muscle strength, 
power, spasticity and contractile function were measured on the weaker leg.  At Visit 3, 
motor unit discharge rates of the vastus lateralis of the weaker leg was measured in the 
Exercise Neuroscience Laboratory.  At Visit 4, magnetic resonance imaging (MRI) of 
the weaker thigh was conducted, in the MRI Center of Cooley Dickinson Hospital. 
Group Characteristics 
Fourteen persons with MS (12 females, 2 males) and 14 age-matched 
individuals without MS (11 females, 3 males) gave signed informed consent, as 
approved by the Institutional Review Board at the University of Massachusetts, 
Amherst.  Participants were recruited from the university and surrounding communities, 
as well as through the Central New England Chapter of the National MS Society.  
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 Participants completed the Spasticity Scale (107), a medical history form, the Physical 
Activity Readiness Questionnaire (119), and a magnetic resonance safety questionnaire.   
Persons with MS were moderately impaired, as determined by their self-reported 
Expanded Disability Status Scale (sEDSS (14)) score of 4.7 ± 1.1 (mean ± SD, range 3-
6).  Of the 14 persons with MS, 13 individuals had relapsing-remitting and 1 individual 
had the primary-progressive subtype.  Medications taken by participants with MS 
included [number of individuals]: immuno-modulators [13], anti-depressants [5], 
analeptics [4], bladder-control medications [3], muscle relaxants [3], and anti-
hypertensives [2] (see Appendix B), and vitamin D supplements [5].  Of the participants 
with MS, 4 indicated having no symptoms of spasticity, 6 had some problems with 
spasticity that did not interfere with their activities, 2 had spasticity that forced them to 
change some of their activities about once a week, and 2 had problems with spasticity 
that forced them to modify their daily activities, based on the Spasticity Scale by Rizzo 
et al. (107).  Participants with MS were excluded if they had an exacerbation within the 
previous 6 months. 
All participants were healthy (other than MS-related symptoms), between the 
ages of 30 and 60 years, had no cardiovascular, neurological or neuromuscular disease 
(other than MS), were free from orthopedic injury in the legs, and were ambulatory.  
Sedentary to recreationally-active participants were recruited for both study groups to 
minimize differences in physical activity level.  Five of the 14 controls were taking the 
following medications [number of individuals]: birth control [2], levothyroxine [2], and 
prilosec [1]. 
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 Anthropometrics.  Height (m) and mass (kg) were recorded, and body mass 
index (BMI; kg·m-2) was calculated.  Leg length (knee joint axis to lateral malleolus of 
fibula) was measured on the tested leg, for calculation of the torque due to inertia (see 
Spasticity). 
Symptomatic Fatigue.  To characterize general fatigue and the impact of fatigue 
on quality of life, participants completed the Fatigue Severity Scale (FSS (60)) and the 
Modified Fatigue Impact Scale (MFIS; 21-items from Fatigue Impact Scale (38)), 
respectively.  Scores for the 21-item MFIS were calculated as a sum of all item 
responses, whereas the 7-item FSS responses were averaged.  Prior to the strength and 
power measures, participants were asked to draw a vertical line on the Visual Analog 
Fatigue Scale (VAFS (112)) to assess symptomatic fatigue at that point in time (i.e., 
“acute” fatigue).  A ruler was used to score the VAFS, as each number (1 through 10) 
was separated by 1 centimeter.  For all fatigue measures, a higher score reflects greater 
fatigue. 
Physical Activity.  To characterize and quantify habitual physical activity level, 
participants wore an accelerometer (GT1M, Actigraph Inc., Pensacola, FL) around their 
waist for 7 days, during all waking hours.  An activity log was also provided for 
participants to record their daily activities and ensure appropriate wear time.  
Acceleration counts were acquired at a sampling frequency of 30 Hz and averaged in 
30-s epochs.  Non-representative days, indicated by self-report in the activity log or 
incomplete data collection, were not included in the analysis.  Data from the 
accelerometer were downloaded using ActiLife software (Actigraph Inc., Pensacola, 
FL) and exported to a Microsoft Excel spreadsheet (Microsoft Corp., Redmond, WA).  
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 Total daily accelerometer counts were averaged across a minimum of 5 days and used 
to represent the participant’s habitual physical activity level (counts·day-1·1000-1) (20; 
65).   
Physical Function.  Physical function was measured to characterize the study 
groups.  Participants were timed for their rapid completion of 5 consecutive chair rises, 
performed without the aid of their arms.  Next, participants were asked to rapidly tap 
their foot for 10 s, one foot at a time, to assess neuromuscular function.  Foot-tapping 
was performed twice and the highest count for each foot used for analysis.  Mobility 
was assessed by having participants walk for 7.62 m (25 ft), first at a brisk and then at a 
usual pace.  Each walk was performed twice and the fastest times were used for 
analysis. 
Isometric Strength and Power 
Isometric Strength.  Participants were seated upright on the Biodex 
dynamometer.  The upper body and thigh were stabilized with straps around the 
shoulder, waist and thigh.  The knee joint was aligned with the axis of the dynamometer 
arm, and the leg was secured to the arm using a Velcro strap.  The knee angle was fixed 
at 90° flexion.  Although the KE was the primary muscle group of interest, knee flexors 
(KF) were also tested for muscle isometric strength.  Torque, velocity, and position data 
were acquired at 2500 Hz using a customized data acquisition program in MATLAB 
software (Math Works Inc., Natick, MA, U.S.A.). 
Three maximal voluntary isometric contractions (MVIC, Nm; 3-4 s duration) 
were obtained in the KE and KF, with 2 min of rest between contractions.  Verbal 
encouragement and visual feedback of torque output (diode light box) were provided to 
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 ensure a maximal effort by the participant.  Maximal effort was confirmed when the 
highest 2 MVIC trials were within 10% of one another.  Additional trials (no more than 
6 trials in total) were performed if this criterion was not met.  The highest peak torque 
was used as the primary outcome measure of muscle isometric strength.     
Power.  Following the isometric strength measures, the total range of motion 
was set at 70°, starting at 90° flexion from full extension.  Participants performed 
maximal voluntary dynamic contractions at a range of velocities between 30 and 300 
°·s-1, at 30 °·s-1 intervals.  Participants performed 2 consecutive maximal voluntary 
dynamic contractions at each velocity, with 3-4 s rest between contractions.  Two min 
of rest between each velocity was provided, to minimize muscle fatigue.  The highest 
power generated at each velocity was recorded.  Peak power was used as the primary 
outcome measure and the velocity at which peak power occurred was used for 
secondary analysis. 
Neural Factors 
Motor Unit Discharge Rates.  Similar to the muscle testing protocol, participants 
were seated upright in a custom-built apparatus, with the knee angle fixed at ~90° 
flexion.  The waist and thighs were secured to the chair by straps to stabilize the body.  
A Velcro strap was used to secure the ankle to a cuff that was connected to a force 
transducer (Interface SM-250, Scottsdale, AZ, U.S.A.).  Participants performed 3 
MVICs (4-5 s duration) of the KE, separated by 2 min of rest, to obtain baseline MVIC 
prior to insertion of the needle electrode.  Verbal encouragement and visual feedback of 
torque output was provided on a computer screen using DasyLab Data Acquisition 
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 software (MicroDAQ.com, Ltd., Contoocook, NH, U.S.A.).  If the 2 highest MVIC 
trials were not within 10% of one another, additional MVIC trials were performed.   
Once peak MVIC was determined, the skin over the patella and belly of the 
vastus lateralis muscle was cleansed with alcohol.  A stainless steel ground electrode 
was taped over the patella.  Then, a sterilized, four-wire needle electrode was inserted 
into the belly of the vastus lateralis, typically in the lower third of the thigh, to record 
intramuscular EMG activity.  The electrode consisted of a 27-gauge stainless steel 
cannula that housed a square array of four 50 μm-diameter platinum-iridium wires, 
which provided 3 recording channels of motor unit activity (52).  The ground and 
needle EMG electrodes were connected to a Dantec Clinical Electromyograph (Dantec 
Counterpoint, Dantec Electronik Medicinsk, Skovlunde, Denmark), where motor unit 
activity was displayed on a digital oscilloscope.  Analog signals from the EMG 
electrode were amplified (200 or 500 μV·division-1) and bandpass filtered (1-10 kHz) in 
the Dantec Clinical Electromyograph.  Signals from the Dantec and force transducer 
were acquired and sampled at 25,600 Hz using DasyLab Data Acquisition software. 
Following insertion of the needle electrode, participants performed 3 MVICs (4-
5 s duration), with 2 min of rest between trials.  Slight adjustments of the needle 
electrode were made between trials to obtain clear recordings of motor unit action 
potentials, as well as to sample different motor units.  Clear recordings were 
characterized as crisp audio feedback and distinct motor unit action potentials displayed 
on the Dantec digital oscilloscope.  Additional MVICs were performed if there were 
fewer than 3 MVICs with clear recordings.   
 71
 Individual motor unit identification was performed using a customized spike 
recognition algorithm program, which automatically identified motor units based on 
discharge history and template-matching (52).  Following auto-identification, motor 
unit identification was verified manually, and superpositioned and mis-identified motor 
units were corrected using a customized motor unit viewing and editing program.  The 
interpulse interval (ms) between consecutive firings of a given motor unit was 
calculated, excluding doublets (≤ 10 ms) and long (≥ 200 ms) intervals.  The discharge 
rate (pulses per second, pps) of a given motor unit was calculated by taking the inverse 
of the interpulse interval.  The highest motor unit discharge rate (maxMUDR) was taken 
from an average of the 5 fastest interpulse intervals of a given motor unit.  To obtain 
one value for each participant, all maxMUDR were averaged across motor units.  As a 
secondary measure, the coefficient of variation of the mean motor unit firings was 
calculated for each motor unit to assess motor unit discharge variability.  All 
coefficients of variation were averaged across motor units to obtain one value for each 
participant. 
Spasticity.  Spasticity was quantified using the passive mode on the Biodex 
dynamometer.  Similar to the power set-up, the total range of motion was set at 70°, 
starting at 90° flexion from full extension.  Participants were asked to remain relaxed 
while the leg was moved passively by the dynamometer.  Torque, velocity and position 
were recorded during passive knee extensions were conducted at 10 °·s-1 and from 30 to 
300 °·s-1, at 30 °·s-1 increments (Figure 5.1A).  Passive torque obtained at 10 °·s-1 
consisted of torque due to gravity and visco-elastic properties of the muscle, and was 
used to correct passive torque obtained at velocities ≥ 30 °·s-1.  Net passive resistive 
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 torque and velocity were averaged across 20° and 50° extension from the starting 
position, for data collected at each velocity setting (Figure 5.1B).  Because the 
dynamometer was unable to passively achieve velocities > 180 °·s-1, a second-order 
polynomial fit was applied to the average passive torque and velocity data for the 
prescribed velocities between 30°·s-1 and 300°·s-1 (Figure 5.1C).  Thus, for each 
participant, the equation obtained from the fit was used to estimate passive torque at all 
velocities achieved during the voluntary dynamic contractions (see Power section, 
above).  Finally, the percentage of KF passive-to-KE voluntary torque was calculated 
for each participant, to examine the contribution of KF spasticity on KE voluntary 
torque production. 
Voluntary Rate of Force Development.  The maximal rate of force development 
during a maximal voluntary contraction was determined by the first derivative of the 
torque trace and expressed as the percentage of peak force per millisecond.  To examine 
group differences in neural contributors to force production, the voluntary rate of force 
development was normalized to the stimulated rate of force development.  See 
Contractile Function section, below, for more detail. 
Muscle Factors 
Contractile Function.  To assess contractile function, 7.6 x 12.7 cm adhesive 
pad electrodes (VQ OrthoCare, Irvine, CA) were placed at the proximal and distal ends 
of the KE muscles.  A stimulus train (80 Hz, 500 ms) was applied using a constant 
current stimulator (model DS7A, Digitimer, Hertfordshire, UK), in an isometric 
condition.  The stimulation intensity was determined by incrementing the current until 
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 50% of MVIC was achieved.  The maximal rate of force development (RFD; % peak 
force·ms-1) was determined from the first derivative of the torque trace. 
Muscle Size.  Magnetic resonance imaging (MRI) of the thigh was conducted 
using a 1.5 Tesla whole-body system (Siemens Medical Solutions USA, Inc., Malvern, 
PA) in the MRI Center at Cooley Dickinson Hospital.  Participants lay supine on a bed 
with 2 phase-array coils placed over the thighs.  The bed was automatically moved into 
the bore so that the mid-thigh was positioned in the isocenter of the magnet.  Forty-six 
T1-weighted axial images were acquired in series, using the following parameters: 256 
x 256 matrix, field of view of 300 mm, 2 averages, and slice thickness of 6 mm with no 
gaps. 
All images were processed using a custom-written MATLAB program.  Slices 
were visually inspected for quality and approximate location of the largest muscle 
cross-sectional area (mCSA).  The largest slice and the 6 to 10 slices on either side of it 
were analyzed.  For each slice, signal intensity thresholds were determined to 
discriminate contractile from non-contractile tissue (58), and the KE muscle group was 
outlined manually.  From this analysis, ~7 of the largest, consecutive fat-free slices 
were identified, re-analyzed, and averaged across trials.  The mean of the 3 largest 
mCSAs (cm2) was used as the measure of muscle size. 
Specific Strength and Specific Power.  Peak isometric torque and power were 
normalized to mCSA, to estimate specific strength (Nm.cm-2) and specific power 
(W.cm-2), respectively. 
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 Statistical Analyses 
All statistical analyses were performed using Statistical Analysis Software (SAS 
Institute Inc., version 8.0, Cary, NC).  Normality tests were conducted on all variables 
to determine the appropriate statistical tests for group comparisons.   
The following tests were performed to address our hypotheses.  Analysis of 
variance (ANOVA) was used to detect group differences in peak isometric torque, peak 
power, mCSA, specific strength, specific power, RFD, maxMUDR, and voluntary RFD 
in the KE muscle group.  Age, gender and physical activity were used as covariates in 
all ANOVA tests, because of their known effects on muscle function.  Non-normally 
distributed variables (peak isometric torque, maxMUDR, voluntary RFD, stimulated 
RFD) were log-transformed and verified for normality prior to performing the ANOVA.  
To detect differences in spasticity (KF passive torque) and its effect on KE power 
across the range of velocities (percentage of KF passive-to-KE voluntary torque), a 2-
factor (group, velocity) repeated measures ANOVA was used.  If significant 
interactions (p≤ 0.05) were observed, Tukey’s post-hoc test was used to determine 
where group differences occurred. 
Statistical analyses were also performed on the descriptive and secondary 
outcome variables.  Unpaired t-tests were used to detect group differences in age, 
height, mass, BMI, foot-tap speed, and MFIS score.  Wilcoxon tests were used to detect 
group differences in physical activity, chair rise time, 7.62 m walk time (usual and brisk 
pace), FSS and VAFS.  Analysis of variance (ANOVA) with covariates of age, gender 
and physical activity level was used to detect group differences in velocity at which 
peak power was achieved, KF MVIC, peak power, coefficient of variation of mean 
 75
 motor unit firings, and stimulated torque.  Because the velocity at which peak power 
was achieved was not normally distributed, this measure was log-transformed prior to 
performing the ANOVA.  Two-factor (group, velocity) repeated measures ANOVA was 
used to detect group differences in power and specific power across the range of 
velocities.  If significant interactions (p≤ 0.05) were observed, Tukey’s post-hoc test 
was used to determine where group differences occurred. 
Linear regressions were performed to examine associations of strength and 
power with mechanisms of weakness and physical function.  These regressions were 
used to clarify the contributions of each mechanism of force production to muscle 
weakness in MS, as well as the impact of weakness on physical function.  An 
interaction term was included in the regression model to test if there were significant 
group differences in the associations of strength and power with mCSA and 
maxMUDR. 
Means ± SD and precise p-values are presented throughout the document, 
including figures and tables.  Significance level was set at p≤ 0.05.   
Results 
Group Characteristics 
Age, height, mass, BMI, and physical activity level were not different between 
groups (Table 5.1).  Compared with non-MS controls, the MS group had greater 
symptomatic fatigue (MFIS, FSS, VAFS), longer time to complete 5 chair rises, lower 
foot-tap speed, and slower walk times (Table 5.1).  One individual with MS was unable 
to perform the chair rise task without the use of her arms; she also had a 3- to 4-fold 
higher time to complete the 7.62 m walk at usual and brisk pace (19.5 s and 18.5 s, 
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 respectively) relative to the MS group.  Therefore, this individual’s values were not 
included in the statistical analyses for group differences in chair rise and walk times. 
Muscle Weakness in MS 
Individuals with MS had lower MVIC torque in the KE (Table 5.2) and KF (46 
± 13 Nm and 64 ± 22 Nm, p=0.0007, respectively) muscles, compared with controls.  
There was a group effect for KE power across velocities that showed lower power 
production in persons with MS compared with controls (p=0.02; Figure 5.2), with no 
group-by-velocity interaction (p=0.13).  Peak power in the KE was lower in MS than 
control (Table 5.2).  The velocity at which peak power was achieved was similar across 
groups (controls: 272 ± 36 °·s-1, MS: 251 ± 45 °·s-1, p=0.16).  Peak torque and power 
were both positively associated with chair rise time, timed 7.62 m usual and brisk walk 
times, and FSS (Table 5.3; see Appendix C for figures). 
Neural Mechanisms 
Motor Unit Discharge Rates.  When participants were asked to perform an 
MVIC with the needle inserted into the muscle for the MUDR recordings, the average 
relative torque achieved tended to be lower in control (81 ± 10 % of baseline MVIC) 
compared with MS (88 ± 9 % of baseline MVIC, p=0.06).  A total of 179 motor units 
were identified (97 for control and 82 for MS).  Maximal MUDR during the MVIC was 
lower in MS (22.7 ± 7.9 pps) compared with control (28.5 ± 8.1 pps, p=0.04; Figure 
5.3).  The coefficient of variation of mean motor unit firings were not different between 
groups (controls: 0.188 ± 0.054, MS: 0.172 ± 0.086, p=0.32).  Maximal MUDR was 
associated with peak torque and peak power (Figure 5.4).  Within the control group, 
maxMUDR was not associated with peak torque (r=0.45, p=0.11) and peak power 
 77
 (r=0.48, p=0.09).  Within the MS group, maxMUDR was associated with peak power 
(r=0.57, p=0.03) but not peak torque (r=0.35, p=0.23).  There were no significant 
differences in the associations (torque-by-maxMUDR interaction, p=0.61; power-by-
maxMUDR interaction, p=0.39) between groups. 
Spasticity.  Knee flexor passive torque across all velocities was not different 
between groups (p=0.31; Figure 5.5A), and there was no significant group-by-velocity 
interaction (p=0.22).  Persons with MS tended to have a higher percentage of KF 
passive-to-KE voluntary torque (Figure 5.5B), and there was no group-by-velocity 
interaction (p=0.56). 
Due to the large amount of variability in spasticity within the MS group, 
individuals with MS were separated into 2 sub-groups: those with spasticity (passive 
torque ≥ 2 SD above controls; n=5) and a non-spastic group (passive torque <2 SD from 
mean for controls; n=9).  Those individuals with spasticity had higher KF passive 
torque compared with the non-spastic group (p=0.0001; Figure 5.6A), indicating 
significant KF spasticity in these individuals.  A significant group-by-velocity 
interaction (p<0.0001) indicated that these individuals had greater passive torque at 
velocities from 180 °·s-1 to 300 °·s-1.  Further, the percentage of KF passive-to-KE 
voluntary torque was higher in this subset compared to the non-spastic MS sub-group 
(p<0.0001; Figure 5.6B).  A significant group-by-velocity interaction (p<0.0001) 
showed that those with spasticity had a greater percentage of KF passive-to-KE 
voluntary torque at velocities of 210 °·s-1 to 300 °·s-1.  There were no differences in 
isometric torque, power, or any measures of force production between individuals with 
and without spasticity in MS (p≥ 0.11; Appendix D).  Notably, within the MS group, 
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 spasticity was modestly associated with physical activity and walk times (r≥ 0.51, p≤ 
0.08), but not associated with time to complete chair rises (r=0.10, p=0.70; Appendix 
E).   
Voluntary Rate of Force Development.  Neither the maximal voluntary RFD, nor 
the voluntary RFD normalized to stimulated RFD, were different between groups 
(Table 5.2).  These results suggest no slowing of neural activation of the muscle during 
an isometric contraction in the MS group compared with controls. 
Muscle Mechanisms 
Muscle Size.  Knee extensor mCSA was lower in MS (n=14) compared with 
control (n=11; Table 5.2).  Muscle size was associated with peak isometric torque and 
peak power (Figure 5.7), for all participants combined.  Within each group, muscle size 
was associated with peak isometric torque (control: r=0.77, p=0.006; MS: r=0.63, 
p=0.02) and peak power (control: r=0.72, p=0.013; MS: r=0.61, p=0.022).  There were 
no significant differences in the associations (torque*mCSA, p=0.79; power*mCSA, 
p=0.995) between groups. 
Specific Strength and Specific Power.  There were no group differences in 
specific strength, but specific power was lower in MS compared with control (Table 
5.2).  Specific power across velocities was lower in MS (n=14) than control (n=11; 
p=0.05; Figure 5.8), with no group-by-velocity interaction (p=0.38).  Maximal MUDR 
tended to be associated with specific power (r=0.55, p=0.06) for all participants 
combined.  There was no association within each group between maxMUDR and 
specific power (control: r=0.72, p=0.11; MS: r=0.45, p=0.79). 
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 Contractile Function.  The rate of force development in response to a stimulated 
contraction was not different between MS and control (Table 5.2), suggesting that rate 
of cross-bridge cycling is similar across groups.   
 
Discussion 
The aim of this study was to identify the mechanisms of muscle weakness in 
persons with MS.  As we hypothesized, persons with MS had lower isometric strength, 
power, MUDR, specific power, and smaller muscle size compared with controls.  
Contrary to our hypotheses, we showed no difference in specific strength, measures of 
spasticity, voluntary RFD, and stimulated RFD between persons with MS and controls.  
Therefore, the primary mechanisms of weakness in MS were lower MUDR and smaller 
muscle size.  Differences in peak isometric torques were abolished when torque was 
normalized to muscle size, indicating that smaller muscle size explains a large portion 
of lower isometric strength.  However, differences in peak dynamic power were reduced 
when power was normalized to muscle size, but specific power remained lower in 
persons with MS compared with controls.  These data suggest that neural factors (i.e., 
MUDR), in addition to smaller muscle size, explain a portion of lower dynamic power 
in persons with MS.  Thus, the mechanisms of weakness in MS may be specific to the 
contraction mode. 
Muscle weakness in MS 
We observed that moderately-impaired persons with MS had lower KE strength 
(23%), KF strength (29%) and KE power (32%) compared with controls.  Our results 
agree with previous studies that have shown 16-57% deficits in isometric (18; 80; 82; 
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 83; 111; 113) and dynamic (3; 16; 21; 63; 99; 121) torque in persons with MS compared 
with controls.  Isometric strength and peak power, respectively, appeared to explain on 
average ~22% and ~17% of the variance in physical function.  These associations 
suggest that muscle weakness may partially affect the performance of activities of daily 
living.  In addition, we observed that isometric strength and power were associated with 
FSS, but not MFIS or VAFS.  The FSS consists of 9-items that focus on physical 
fatigue, whereas the 21-item MFIS focus on physical and mental fatigue and the VAFS 
describes global fatigue.  Thus, muscle weakness may partially explain physical fatigue 
experienced by some of the participants. 
Smaller muscles, similar specific strength, and lower specific power in MS 
The KE have been shown to be vulnerable to atrophy during disuse in the 
elderly (1; 27).  Despite no group difference in physical activity (Table 5.1), we showed 
that persons with MS had a 17% lower maximal mCSA compared with controls.  In this 
study, the mCSA values were comparable to those observed by White et al. (127) in the 
KE.  Muscle size accounted for ~55% of the variance in isometric strength and dynamic 
power (Figure 5.7), indicating that smaller muscle size explains a significant portion of 
the muscle weakness observed in persons with MS.  This relationship has also been 
observed in the elderly in the ankle dorsiflexor muscles (56). 
Specific strength of the KE was not different between MS and control, 
suggesting that muscle quality was similar across groups in the isometric condition.  
This result agrees with Kent-Braun et al. (57), who observed no difference between MS 
and control in specific strength of the ankle dorsiflexors.  To our knowledge, we are the 
first to show lower specific power in MS compared with control, suggesting that neural 
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 factors, such as lower MUDR, were likely explaining lower peak power production in 
MS. 
No difference in the RFD during a stimulated contraction across groups 
The maximum RFD elicited by electrical stimulation has been used in previous 
studies as a measure of the rate of cross-bridge cycling (28; 30; 113).  We observed no 
difference in the RFD in the KE between persons with and without MS, suggesting that 
the rate of cross-bridge cycling was similar across groups.  De Haan et al. (28) have 
observed no differences in RFD between MS and control, using a current intensity to 
elicit 30% MVIC in the KE.   The lack of difference in RFD between groups may be 
that the current intensity used to elicit submaximal torque was insufficient to recruit all 
muscle fibers.  However, using a supramaximal stimulus, de Ruiter et al. (30) showed 
similar RFD across groups in the adductor pollicis muscle, whereas Sharma et al. (113) 
showed lower RFD in the ankle dorsiflexors in MS compared with control.  At the 
single fiber level, cross-bridge kinetics were not different between persons with MS and 
controls (17; 44), supporting our observations.  Thus, cross-bridge kinetics are likely 
not a mechanism for muscle weakness in persons with MS. 
Slower MUDR in persons with MS 
We observed that persons with MS had ~20% slower maximal MUDR in the 
vastus lateralis muscle compared with controls.  Only one other study has examined 
MUDR during a MVIC and observed ~ 46% lower maxMUDR in a small group of 4 
ambulatory persons with MS compared with 16 controls (106).  Notably, motor unit 
discharge variability during a maximal voluntary contraction was not different between 
groups, suggesting that the pattern of motor unit discharges is similar between MS and 
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 control.  No studies have examined motor unit discharge variability during maximal 
contractions in persons with MS compared with control.  However, Dorfman et al. (33) 
observed increased motor unit discharge variability in MS compared with control 
during submaximal contractions in various muscle groups (brachial biceps, brachial 
triceps, anterior tibial).   
Slower rate-coding may be a consequence of demyelination in MS, generating 
prolonged motor conduction (12; 43; 123) and after-hyperpolarization period (10; 12) in 
persons with MS.  Redistribution of sodium channels in the demyelinated areas of the 
axon (25) may explain the slowed recovery of the motor neuron (10; 12).  Maximal 
MUDR may account for ~31% and 26% of the variance in isometric strength and 
power, respectively, indicating the importance of rate-coding on both contraction 
modes.  In addition, maximal MUDR was shown to explain 25% of the variance in 
specific power, suggesting that rate-coding may be one mechanism of specific power.   
Spasticity in MS 
Spasticity can be a significant problem in persons with MS.  Spasticity in an 
antagonist muscle is a potential mechanism for power loss in an agonist muscle, 
because of the antagonist’s resistance to passive movement due to a hyperexcitable 
stretch reflex (64).  Antagonist co-activation may slow the velocity of a dynamic 
contraction and, thus, decrease the power generated by an agonist muscle.  This 
phenomenon could explain some of the muscle weakness in MS, particularly during 
high-velocity contractions.  Using the dynamometer, we showed no difference in KF 
passive torque during knee extension between persons with MS and controls.  The 
percentage of KF passive-to-KE voluntary torque was slightly higher in persons with 
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 MS compared with controls, although this was not statistically significant.  In a sub-
group of individuals with spasticity, we observed higher contributions of KF passive 
torque to lower KE voluntary torque compared with a non-spastic group during 
maximal voluntary dynamic contractions (Figure 5.6).  However, a larger sample of 
individuals with and without spasticity in MS is needed to elucidate the role of 
spasticity on physical activity and physical function. 
Contrary to our findings, Nuyens et al. (90) observed a velocity-dependent 
increase in KE and KF passive torque production at the muscle’s most stretched 
position in persons with MS.  The discrepancy between studies may be due to different 
populations of MS individuals studied.  We recruited mild-to-moderately impaired, 
ambulatory individuals with MS; whereas Nuyens et al. (90) studied highly-impaired 
persons with MS, most of whom used wheelchairs.  Spasticity may reside in muscles 
other than the knee flexors, and future studies are needed to clarify the contribution of 
antagonist muscle spasticity on agonist power production in other muscle groups.   
The measure of spasticity using the dynamometer is not without limitations.  
Although settings were made to dictate the velocity of passive movement, target 
velocity was not achieved during passive movements at settings >180 °·s-1, due to 
constraints in the dynamometer preset by the manufacturer.  Because we were interested 
in examining the effect of KF spasticity on KE power production, a quadratic equation 
was determined for each individual to estimate torque resistance at the same velocities 
achieved by each person during maximal voluntary dynamic contractions, to overcome 
the limitations of the dynamometer.  A major assumption in this approach was that 
resistive torque at velocities greater than >180 °·s-1 would increase in a quadratic 
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 manner.  Overcoming this limitation in the acceleration setting would allow a better 
understanding of the passive torque-velocity relationship to characterize spasticity. 
Voluntary RFD is not different across groups 
We observed no difference in either voluntary RFD or normalized RFD between 
MS and control (Table 5.2), suggesting that neural activation of force production was 
not different across groups during an isometric contraction.  This data supports our lack 
of difference in specific strength, where group differences in isometric strength were 
abolished when torque was normalized to muscle size.  High frequency bursts of motor 
unit discharges have been observed in young men during voluntary rate of force 
development during fast, ballistic contractions (32).  Thus, during isometric 
contractions, muscle activation pattern may not be different between persons with MS 
and controls. 
Although Desmedt et al. (32) showed high rate-coding during ballistic isometric 
contractions, the results provide some insight to the potential role of rate-coding in 
contraction velocity of power production.  Because dynamic contractions were ballistic, 
rate-coding may have had a substantial role in producing maximal power, particularly 
during high-velocity contractions.  It may be that rate-coding during force development 
may not be different between MS and control and likely explain the lack of difference 
in RFD across groups.  Unfortunately, we were not able to reliably measure rate-coding 
during dynamic contractions, due to noise artifacts and the loss of motor unit potentials, 
particularly during rapid movement.   
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 Future Directions 
In this study, we have shown differences in isometric strength, power, specific 
power, MUDR and muscle size between persons with and without MS.  Previous 
research has shown that resistance training can improve all of these variables.  
Resistance training has been shown to be effective in increasing strength and power in 
persons with MS (31; 48; 118; 127).  However, the specific adaptations explaining the 
increase in isometric strength and power have not been determined.  It is well 
recognized that long-term resistance training can increase muscle size.  Neural 
adaptations have also been shown to occur during short-term resistance training in non-
MS adults (52; 69; 95; 122).  Studies in older adults have shown increases in maximal 
motor unit discharge rates (52) and a reduction in antagonist co-activation (49) 
following resistance training.  Because the pathophysiology of MS affects the central 
nervous system, it is not known whether neural adaptations would be blunted following 
short-term resistance training.  However, resistance training studies in MS showed 
improvements in power without increases in muscle mass (115; 127), suggesting that 
neural factors may be contributing to improvements in power production.  Additional 
studies are needed to determine the mechanistic adaptations to a resistance training 
program in persons with MS. 
Conclusion 
The important mechanisms of muscle weakness in MS appear to be smaller 
muscle size and lower MUDR, each of which may contribute differently to weakness 
depending on contraction mode.  The identification of these mechanisms provides an 
evidence-based rationale for the use of a resistance training intervention to increase 
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 strength and power in persons with MS.  The improvement and maintenance of neural 
activation and muscle size through resistance training may allow persons with MS to 
increase their physical activity, manage symptoms of MS, and improve their quality of 
life. 
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 Figure legends 
5.1. Spasticity data for a female with MS.  A) Individual torque traces during knee 
extension for each velocity, corrected for torque due to inertia.  The x-axis 
represents the range of motion with 0° being the starting position of 90° flexion.  
B) Net torque traces, calculated by subtracting torque from 10 °·s-1 for each 
velocity to correct for gravity and visco-elastic properties of the muscle.  Torque 
was averaged across 20-50° extension, indicated by the bar.  C) Torque averaged 
across 20-50° extension, for each velocity.  The data were fit to a second-order 
polynomial and the derived equation was used to estimate torque at the same 
velocities achieved during voluntary dynamic contractions. 
5.2. MS had lower KE power across velocities compared with control (p=0.02).  Data 
are mean ± S.D.  n=14 in each group. 
5.3. Lower maximal MUDR of the vastus lateralis muscle was observed in persons 
with MS (22.7 ± 7.9 pps) compared with controls (28.5 ± 8.1 pps, p=0.04) during 
maximal voluntary isometric contractions.  n=14 in each group.  Square symbols 
denote group mean with standard deviation bars.  Circles and triangles represent 
women and men, respectively. 
5.4. Maximal MUDR was associated with peak isometric torque (A; r=0.56, p=0.002) 
and peak dynamic power (B; r=0.51, p=0.005).  n=14 in each group for each 
variable.  Within the control group, maxMUDR was not associated with peak 
torque (r=0.45, p=0.11) and peak power (r=0.48, p=0.09).  Within the MS group, 
max MUDR was associated with peak power (r=0.57, p=0.03) but not peak torque 
(r=0.35, p=0.23). 
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 5.5. There was no difference in KF passive torque (A) between MS and control 
(p=0.31).  MS tended to have a higher percentage of KF passive-to-KE voluntary 
torque (B) compared with controls (p=0.067).  Data are mean ± S.D.  n=14 in each 
group. 
5.6. Participants with MS were separated into 2 sub-groups:  those with spasticity 
(passive torque ≥2 SD above control; n=5) and a non-spastic group (passive 
torque <2 SD from mean for controls; n=9).  Individuals with spasticity had higher 
KF passive torque compared with the non-spastic sub-group (p=0.0001; A).  
Further, the percentage of KF passive-to-KE voluntary torque was higher in 
persons with spasticity than non-spastic sub-group (p<0.0001; B).  * indicates a 
significant group x velocity interaction (p<0.0001). 
5.7. Knee extensor muscle size is associated with peak isometric torque (A; r=0.75, 
p<0.001) and peak power (B; r=0.74, p<0.0001).  Within each group, muscle size 
was associated with peak isometric torque (control: r=0.77, p=0.006; MS: r=0.63, 
p=0.02) and peak power (control: r=0.72, p=0.013; MS: r=0.61, p=0.022).  n=14 
in each group for isometric torque and power.  For mCSA, n=11 for control and 
n=14 for MS. 
5.8. MS (n=14) had lower specific power across velocities compared with control 
(n=11; p=0.05).  Data are mean ± S.D. 
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 Table 5.1.  Group Characteristics 
 
Data are presented as means ± S.D.  C.I., 95% confidence interval for the difference in 
means across groups; BMI, body mass index; MFIS, Modified Fatigue Impact Scale; 
FSS, Fatigue Severity Scale; VAFS, Visual Analog Fatigue Scale.  --, no C.I. because 
variables were non-normally distributed.  All variables have n=14 in each group, except 
for chair rise and 7.62 m walk times (n=14 controls, 13 MS). 
Variable Control MS C.I. p value 
Age (years) 46 ± 7 48 ± 9 -8.5, 4.2 0.49 
Height (m) 1.68 ± 0.10 1.66 ± 0.08 -0.05, 0.09 0.53 
Mass (kg) 73.4 ± 16.3 74.7 ± 13.6 -13.0, 10.4 0.82 
BMI (kg·m-2) 25.7 ± 4.4 26.9 ± 4.1 -4.5, 2.0 0.44 
Physical Activity  
(counts·day-1·1000-1) 259 ± 146 193 ± 92 -- 0.26 
MFIS 15 ± 15 37 ± 14 -32.7, -10.0 0.0006 
FSS 2.3 ± 1.1 4.5 ± 1.8 -- 0.002 
VAFS 1.5 ± 0.7 2.7 ± 1.9 -- 0.02 
Chair rise time (s) 8.26 ± 2.09 12.93 ± 4.13 -- 0.001 
Foot-tap speed                   
(counts in 10 s)      left 47 ± 10 35 ± 7 5.3, 18.7 0.001 
                                            right 50 ± 10 36 ± 8 7.1, 21.5 0.004 
7.62 m walk time (s)          usual 5.08 ± 0.60 6.02 ± 0.91 -- 0.01 
                                            brisk 3.86 ± 0.45 4.47 ± 0.83 -- 0.06 
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 Table 5.2.  Knee Extensor Muscle Characteristics 
Data are presented as means ± S.D.  mCSA, fat-free muscle cross-sectional area; RFD, 
maximal rate of force development.  Voluntary RFD was normalized to stimulated RFD 
and expressed as a percentage.  All variables have n=14 in each group, except mCSA, 
peak specific strength and peak specific power (n=11 controls, 14 MS). 
Variable Control MS p value 
Peak Isometric Torque (Nm) 140 ± 51 108 ± 29 0.03 
Peak Power (W) 320 ± 136 216 ± 73 0.002 
mCSA (cm2) 52.9 ± 14.8 43.9 ± 7.8 0.04 
Specific Strength (Nm·cm-2) 2.63 ± 0.67 2.46 ± 0.49 0.48 
Specific Power (W·cm-2) 6.09 ± 1.69 4.92 ± 1.28 0.05 
Stimulated RFD (% peak force·ms-1) 1.24 ± 0.29 1.15 ± 0.39 0.37 
Voluntary RFD (% peak force·ms-1) 0.66 ± 0.29 0.64 ± 0.20 0.81 
Voluntary-to-simulated RFD*100 (%) 53 ± 17 58 ± 21 0.44 
 
 
 
 92
 Table 5.3.  Associations between KE strength, peak power, physical function and 
symptomatic fatigue   
FSS, Fatigue Severity Scale; MFIS, Modified Fatigue Impact Scale; VAFS, Visual 
Analog Fatigue Scale. 
 KE strength (Nm) KE peak power (W) 
Variable r p-value r p-value 
Chair rise time (s) 0.42 0.03 0.44 0.02 
7.62 m walk time (s)         usual 0.46 0.02 0.39 0.04 
                                           brisk 0.53 0.005 0.42 0.03 
FSS 1.00 <0.0001 0.44 0.02 
MFIS 0.32 0.10 0.28 0.14 
VAFS 0.26 0.19 0.17 0.40 
 
 93
 Figure 5.1.  Spasticity data for a female with MS 
 
Angle (°)
-10 0 10 20 30 40 50 60 70 80
P
as
si
ve
 to
rq
ue
 (N
m
)
-5
0
5
10
15
20
25
30
baseline (10 dps)
30 dps
60 dps
90 dps
120 dps 
150 dps
180 dps
210 dps 
240 dps
270 dps
300 dps
Angle (°)
0 10 20 30 40 50 60 70
P
as
si
ve
 to
rq
ue
 (N
m
)
-1
0
1
2
3
4
5
Velocity (°·s-1)
20 40 60 80 100 120 140 160 180 200
M
ea
n 
ne
t t
or
qu
e 
(N
m
)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
C
A
B
 
A) Individual torque traces 
during knee extension 
for each velocity, 
corrected for torque due 
to inertia.  The x-axis 
represents the range of 
motion with 0° being 
the starting position of 
90° flexion. 
 
 
 
 
B) Net torque traces, 
calculated by 
subtracting torque from 
10 °·s-1 for each 
velocity to correct for 
gravity and visco-elastic 
properties of the 
muscle.  Torque was 
averaged across 20-50° 
extension, indicated by 
the bar. 
 
 
 
C) Torque averaged across 
20-50° extension, for 
each velocity.  The data 
were fit to a second-
order polynomial and 
the derived equation 
was used to estimate 
torque at the same 
velocities achieved 
during voluntary 
dynamic contractions 
for each participant. 
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 Figure 5.2.   
 
MS had lower KE power across velocities compared with control (p=0.02).  Data are 
mean ± S.D.  n=14 in each group. 
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 Figure 5.3. 
Lower maximal MUDR of the vastus lateralis muscle was observed in persons with MS 
(22.7 ± 7.9 pps) compared with controls (28.5 ± 8.1 pps, p=0.04) during maximal 
voluntary isometric contractions.  n=14 in each group.  Square symbols denote group 
mean with standard deviation bars.  Circles and triangles represent women and men, 
respectively. 
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 Figure 5.4.   
 
Maximal MUDR was associated with peak isometric torque (A; r=0.56, p=0.002) and 
peak dynamic power (B; r=0.51, p=0.005).  Within the control group, maxMUDR was 
not associated with peak torque (r=0.45, p=0.11) and peak power (r=0.48, p=0.09).  
Within the MS group, max MUDR was associated with peak power (r=0.57, p=0.03) 
but not peak torque (r=0.35, p=0.23).  n=14 in each group for each variable.   
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 Figure 5.5.   
There was no difference in KF passive torque (A) between MS and control (p=0.31).  
MS tended to have a higher percentage of KF passive-to-KE voluntary torque (B) 
compared with controls (p=0.067).  Data are mean ± S.D.  n=14 in each group. 
Velocity (°·s-1)
0 30 60 90 120 150 180 210 240 270 300
K
F 
pa
ss
iv
e-
to
-K
E
 v
ol
un
ta
ry
 to
rq
ue
 (%
)
0
10
20
30
40
50
P
as
si
ve
 to
rq
ue
 (N
m
)
0
2
4
6
8
10
12
14
16
Control
MS
A
B
 
 98
 Figure 5.6.   
 
Participants with MS were separated into 2 sub-groups:  those with spasticity (passive 
torque ≥2 SD above control; n=5) and a non-spastic group (passive torque <2 SD from 
mean for controls; n=9).  Individuals with spasticity had higher KF passive torque 
compared with the non-spastic sub-group (p=0.0001; A).  Further, the percentage of KF 
passive-to-KE voluntary torque was higher in persons with spasticity than non-spastic 
sub-group (p<0.0001; B).  * indicates a significant group x velocity interaction 
(p<0.0001). 
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 Figure 5.7.   
Knee extensor muscle size is associated with peak isometric torque (A; r=0.75, 
p<0.001) and peak power (B; r=0.74, p<0.0001).  Within each group, muscle size was 
associated with peak isometric torque (control: r=0.77, p=0.006; MS: r=0.63, p=0.02) 
and peak power (control: r=0.72, p=0.013; MS: r=0.61, p=0.022).  n=14 in each group 
for isometric torque and power.  For mCSA, n=11 for control and n=14 for MS. 
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Figure 5.8. 
MS (n=14) had lower specific power across velocities compared with control (n=11; 
p=0.05).  Data are mean ± S.D. 
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 CHAPTER 6 
PRÉCIS OF DISSERTATION 
Novelty 
This dissertation study was the first to systematically address neural and 
muscular mechanisms of muscle weakness in persons with MS compared with age- 
matched controls.  The results of this dissertation suggest that lower motor unit 
discharge rates and smaller muscle size are primary mechanisms of knee extensor 
weakness in MS.  Differences in isometric strength across groups were abolished when 
torque was normalized to muscle size.  Differences in dynamic power were lessened 
when muscle size was accounted for, but specific power remained lower in persons with 
MS compared with controls, suggesting that neural factors explains some of the lower 
power production in persons with MS.  These results suggest that mechanisms of 
weakness in MS may be contraction-mode specific.   
This dissertation study was also the first to examine the role of spasticity in the 
KF on dynamic power production in the KE.  Spasticity in an antagonist muscle may 
impede the velocity component of power production in an agonist muscle.  In persons 
with MS, 5 individuals with spasticity in the knee flexor muscles had higher KF passive 
torque, and the percentage of KF passive-to-KE voluntary torque was large during high-
velocity contractions compared with a non-spastic subgroup.  These results suggest that 
spasticity in an antagonist muscle may act to co-activate during agonist power 
production, and thereby, contribute to some of the weakness in persons with MS.  
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 Significance and Impact 
The significance of this dissertation study is identification of key mechanisms 
(lower motor unit discharge rates and smaller muscle size) of muscle weakness within 
the same sample population with MS compared with age-matched controls.  The 
contribution of lower motor unit discharge rates and smaller muscle size has been 
shown to be contraction-mode dependent.  While lower isometric strength was largely 
explained by smaller muscle size, lower dynamic power was attributed to changes in 
neural function, in addition to smaller muscle size.  Muscle size and motor unit 
discharge rates have been shown to improve with a resistance training program in non-
MS adults.  Thus, this dissertation provides evidence-based knowledge for resistance 
training intervention to ameliorate weakness by specifically addressing muscle size and 
motor unit discharge rates in MS. 
Future Directions 
Study 1 of this dissertation has provided key mechanisms of weakness in person 
with MS: muscle atrophy and altered neural function.  These results provide the 
foundation for the proposed Study 2 of this dissertation, examining the effect of 2 
weeks of high-intensity resistance training (3 times per week) on muscle strength, 
power, motor unit discharge rates, and antagonist muscle co-activation in persons with 
and without MS.  In general, short-term resistance training is known to improve neural 
factors of force production (69), such as increasing motor unit discharge rates (52) and 
reducing antagonist co-activation (49).  Eight- to 10-week resistance training programs 
in persons with MS have demonstrated increases in strength and power (31; 115; 118; 
127) without any increases in muscle size (115; 127), suggesting that neural adaptation 
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 was largely accounting for strength and power improvements.  However, no studies 
have specifically measured neural adaptation in persons with MS.  Thus, Study 2 will 
elucidate whether neural adaptations (e.g., motor unit discharge rates) occur following 
short-term resistance training in persons with MS and whether the magnitude of neural 
adaptation is similar or blunted in persons with MS compared with controls. 
Therapeutic interventions may need to target the weaker limb more so than both 
limbs together.  Anecdotally, persons with MS have indicated that one limb presents 
more symptomatic problems than the other.  Power asymmetry in the KE muscles has 
been observed in persons with MS (21).  Because Study 1 examined only the weaker 
leg, it may be that therapeutic interventions will need to focus more on the weaker leg 
rather than both legs to minimize limb asymmetries, which have been associated with 
postural imbalances, lower physical function and symptomatic fatigue (21).  Thus, it 
would be interesting to examine whether resistance training in the weaker limb 
minimizes power asymmetry and how the mechanisms of this improvement might 
affect the trained and untrained limbs in persons with MS. 
Further research into the role of spasticity on power production in MS is needed.  
Spasticity has a tremendous impact on physical function and overall quality of life.  
Although we did not show spasticity in the KF in 9 of the 14 participants with MS, 
spasticity may reside in other muscle groups (e.g., knee extensors, plantarflexors) and 
may affect the opposing muscle’s ability to generate maximal power production.  
Quantifying spasticity in other muscles, and its impact on power production in opposing 
muscles, is warranted.  In addition, the effects of resistance training on spasticity have 
not yet been explored in MS.  A reduction of spasticity following an acute bout of 
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 unloaded leg cycling has been observed in persons with MS (73; 74).  Therefore, a 
combination of resistance training and cycling may be a more effective approach in 
mitigating symptoms of MS that affect force production. 
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 Abstract 
A higher energy cost of walking (Cw) is sometimes observed in persons with multiple 
sclerosis (MS), and could contribute to their greater symptomatic fatigue.  Objective:  
To compare Cw at 3 walking speeds in MS and controls, and to examine the 
interactions between Cw, symptomatic fatigue and perceived exertion.  Design:  Non-
randomized controlled study.  Setting:  Muscle Physiology and Energy Metabolism 
Laboratories.  Participants:  Ten persons with MS and 14 age-matched controls.  Main 
Outcome Measures:  Oxygen consumption (VO2) was obtained by open-circuit 
spirometry and indirect calorimetry at rest and during treadmill walking at 0.6 m·s-1 and 
1.4 m·s-1, and at a self-selected, preferred speed.  Cw was calculated as net VO2 
(walking minus rest; ml·kg-1·m-1).  Fatigue and perceived exertion were obtained using 
a visual analog fatigue scale and modified Borg scale, respectively.  Results:  Preferred 
speed was not different between groups.  Cw was higher in MS compared with controls 
across all walking speeds (p=0.003), with a group-by-speed interaction indicating 
higher Cw in MS during 0.6 m·s-1 (p=0.001), but not 1.4 m·s-1 or preferred speeds, 
compared with controls.  MS had greater fatigue and perceived exertion (p≤ 0.004) at 
all speeds compared with controls.  Cw was associated with perceived exertion during 
slow and preferred speeds (r≥ 0.41, p≤ 0.05), but was not associated with fatigue (r≤ 
0.35, p≥ 0.10).  Conclusions:  Despite similar preferred speeds, and Cw at preferred and 
fast speeds, this MS group exhibited higher fatigue and exertion at all walk speeds.  
However, only slow walking induced sufficient challenges to postural control to elicit 
higher energy costs in MS.  These results suggest that increased postural demands on 
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 individuals with MS at slower walking speeds may require increased muscular 
contributions to maintain balance. 
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 Introduction 
 Multiple sclerosis (MS) is an auto-immune disease that is defined by 
demyelination of nerves in the central nervous system.  Symptoms of MS include 
symptomatic fatigue, increased perceived exertion, balance problems, and difficulty in 
walking.  These symptoms may have a major effect on the ability to perform activities 
of daily living and alter physical activity behaviors in persons with MS.   
 Gait abnormalities, such as slower gait speed (7; 21; 67; 70; 111; 120; 121), 
shorter stride length (7; 67; 121), lower cadence (7; 121), and prolonged double-support 
phase (7; 67) are often observed in persons with MS.  Altered gait characteristics and a 
lower preferred walking speed may be functional strategies adopted by individuals with 
MS to minimize the risk of falling (21; 104), given that individuals with MS 
demonstrate compromised balance.  However, these strategies may, in turn, increase the 
energy cost of walking (Cw), defined as the net rate of oxygen consumption (VO2; 
walking minus resting) per body mass and distance traveled (ml O2·kg-1·m-1).   
 The metabolic rate while walking primarily reflects the energy costs associated 
with muscle activation for maintenance of balance, coordination and posture while 
propelling the body forward.  In healthy adults, the relationship between Cw and 
walking speed has been characterized as a U-shaped curve by Ralston (101); with the 
lowest VO2 typically occurring at a preferred walking speed and higher VO2 at lower 
and higher speeds, reflecting increased Cw.  Individuals with MS have shown higher 
Cw, compared with controls, over a range of slow and fast treadmill walking speeds 
(91; 93), but not at preferred walking speed.  This systematic alteration of Cw across a 
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 range of speeds in individuals with MS may suggest their use of different postural 
control strategies compared with controls. 
 Fatigue, defined as an overwhelming sense of tiredness, is a highly problematic 
symptom of MS (61).  It is reasonable to suppose that higher Cw may increase feelings 
of fatigue.  This could occur both directly, as a result of higher energy expenditure, or 
indirectly as a result of elevated body core temperature (61; 126).  Heat generated from 
higher amounts of muscular activity (i.e., reflecting higher Cw) may exacerbate 
symptomatic fatigue in persons with MS.  In turn, a worsening of fatigue during 
walking, regardless of the cause, could contribute to higher levels of perceived exertion 
(or perceptual effort) in persons with MS compared with controls, an effect that could 
act to limit physical activity behavior in persons with MS. 
 Therefore, the aim of this study was to quantify the Cw associated with 
prescribed (slow and fast) and preferred walking speeds in persons with MS compared 
with age-matched controls, and to explore the relationships between Cw, fatigue, 
perceived exertion and physical activity in MS.  We hypothesized that persons with MS 
would have higher Cw across all speeds compared with controls.  We also hypothesized 
that symptomatic fatigue and ratings of perceived exertion (RPE) would be lower at 
preferred speed compared to the slow and fast speeds, due to lower Cw at this speed.  
Finally, we examined whether Cw was associated with symptomatic fatigue, perceived 
exertion or habitual physical activity level in our study groups. 
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 Methods 
Participants 
 Ten persons with MS (9 females, 1 male) and 14 age-matched individuals 
without MS (11 females, 3 males) gave signed informed consent, as approved by the 
Institutional Review Board at the University of Massachusetts, Amherst, and in 
compliance with the Declaration of Helsinki.  Of the 10 individuals with MS, 9 had 
relapsing-remitting and 1 had primary progressive subtypes.  Participants were recruited 
from the university and surrounding communities, as well as through the New England 
Chapter of the National MS Society. 
Participants were excluded from the study if they had metabolic, non-MS 
neurological, cardiovascular or other major diseases; cognitive impairment or mental 
disorder that prevented them from following instructions; orthopedic injury or 
significant arthritis in the legs; or were unable to walk at a speed of 0.6 m·s-1.  
Participants with MS were ambulatory: 7 walked unaided, and 3 needed a cane or 
Canadian crutch.  No participant with MS had an exacerbation within 6 months prior to 
their involvement in the study.  Disease duration was 12 ± 8 years (mean ± SD; range 4 
to 27 years).  Medications taken by the participants with MS included [# of 
participants]: immunomodulators [9], anti-depressants [4], anti-convulsants [3], anti-
anxiety [3], anti-spasticity [2], medications for bladder control [2] and for wakefulness 
[2].  Five of the 14 controls were taking the following medications [# of participants]: 
birth control [2], levothyroxine [2] and prilosec [1]. 
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 Study Design 
 After an overnight fast (~9 hours), participants reported to the Muscle 
Physiology Laboratory between 7:00 and 10:00am, where they completed the informed 
consent process, self-reported Expanded Disability Status Scale (sEDSS (14)), medical 
history form, and Physical Activity Readiness Questionnaire (119).  Height (m) and 
body mass (kg) were determined, and body mass index (BMI; kg·m-2) was calculated.  
Participants completed the Fatigue Severity Scale (FSS (60)) and Modified Fatigue 
Impact Scale (MFIS; 21-items from Fatigue Impact Scale (38)) to characterize 
participant’s fatigue status in the prior 2 and 4 weeks, respectively.  Participants were 
asked to walk 7.62 m over ground at a brisk pace and then at a preferred pace.  Each 
pace was performed twice, and the fastest time (s) for each pace was reported.  
Following these tests, measures of resting metabolic rate and Cw were collected in 
climate-controlled laboratories.  Prior to leaving, participants were given an 
accelerometer (GT1M, Actigraph Inc., Pensacola, FL) to wear for 7 days to monitor 
habitual physical activity.   
Energy cost of walking 
 Metabolic rate was measured at rest while the participant lay supine on a bed, 
and during the 3 treadmill walking speeds.  Gas exchange measurements were obtained 
continuously throughout each test by open-circuit spirometry and indirect calorimetry 
(TrueMax2400 Metabolic Measurement System, Parvomedics, Salt Lake City, UT).  
Pneumotachometer (to measure volume) and standard gas (16.01% O2 and 3.98% CO2) 
calibrations were performed prior to each testing session.  As participants breathed 
using a one-way valve mouthpiece, expired air was collected and delivered to the 
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 mixing chamber via a hose.  A caliper was placed over the nose to ensure that breathing 
was through the mouth only.  Participants were instructed to lay supine quietly on a bed 
for ~15 minutes to reach and maintain steady-state, defined as the balance between 
energy required by working muscles and the rate of ATP production (via oxidative 
metabolism).  Then, metabolic measures were made for 6-8 min.  Resting metabolic rate 
(VO2rest) was recorded as the average rate during the final 2 minutes of this period. 
Following measurement of VO2rest, participants walked for ~5 min on a treadmill 
at each of the 3 speeds, in the following order: 0.6 m·s-1, 1.4 m·s-1, and at a self-
selected, preferred speed.  Walking speed was ordered in this way to 1) make certain 
that participants with MS were able to perform the slow walking speed (particularly 
with those who used walking aids), and 2) familiarize each person with the fast walking 
speed prior to determining their preferred walking speed.  Preferred walking speed was 
determined in an oscillatory-decaying manner.  Using ~10-s epochs, the investigator set 
fast and slow speeds, alternately, decreasing the range with each repetition until the 
participant indicated their usual walking speed.  Verbal encouragement was provided to 
all participants during each walking speed.  All participants with MS lightly touched the 
handrails for extra sensory support.  A second investigator was positioned behind the 
treadmill to provide tactile feedback on the back if the participant was walking to close 
to the end of the treadmill.  Seated rest periods of 5 to 10 min and cold drinks of water 
were provided between walking speeds.   
For each speed trial, oxygen consumption (VO2walk; ml·kg-1·min-1) was averaged 
over the final 2 minutes when steady-state was maintained, and the net VO2 (walking 
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 minus resting) was used to calculate Cw (ml O2·kg-1·m-1) during slow (Cwslow), fast 
(Cwfast), and preferred (Cwpref) walking speeds (Equation 1). 
Cw = 
v
VOVO restwalk 22 −     Equation 1 
where v is treadmill speed (93).  
Symptomatic Fatigue and Rating of Perceived Exertion (RPE) 
 Symptomatic fatigue and RPE were measured while standing quietly on the 
treadmill prior to the first walking trial and again immediately following each treadmill 
trial.  Acute symptomatic fatigue was measured using the visual analog fatigue scale 
(VAFS) (112; 129).  Participants were asked to draw a vertical line across a scale 
marked 1 through 10, with each number separated by 1 cm.  A ruler was used to 
measure and score each VAFS, with a smaller score indicating less fatigue.  The 
modified Borg scale was used to obtain RPE (13; 71; 129).  For the post-walk measures, 
participants were asked to indicate the VAFS and RPE based on how they felt during 
the last 30 s of walking. 
Physical Activity 
 Participants were given an accelerometer (Actigraph Inc., Pensacola, FL) to 
wear around the waist for 7 days during waking hours, to monitor habitual physical 
activity.  An activity log was also provided for participants to record their daily 
activities.  A minimum of 5 days were included in the analysis of physical activity.  
Days that were not typical of habitual physical activity, indicated by self-report on the 
activity log, were excluded.  Data from the accelerometer were downloaded using 
Actigraph’s ActiLife software and exported to a Microsoft Excel spreadsheet.  Total 
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 daily accelerometer counts were averaged across days and divided by 1000 for ease of 
reporting (counts·day-1·1000-1) (81). 
Statistical Analyses 
 All statistical analyses were performed using Statistical Analysis Software (SAS 
Institute Inc., version 8.0, Cary, NC).  Normality tests were conducted on all variables 
prior to proceeding with the statistical analyses, to determine the appropriate use of 
parametric and non-parametric tests.   
 Unpaired t-tests were used to examine group differences in age, height, body 
mass, BMI, FSS, MFIS, 7.62 m walk time, preferred speed, and VO2rest.  Wilcoxon tests 
were used to examine group differences in physical activity and baseline VAFS.  Two-
factor (group, speed) repeated measures analysis of variance was used to detect 
differences between groups in Cw, RPE and VAFS across all walking speeds.  Linear 
regression was used to examine associations between Cw and physical activity, as well 
as between Cw, fatigue and RPE at each walking speed.  Data are presented as means ± 
SD, and precise p-values and 95% confidence intervals are reported where appropriate. 
 
Results 
Participants 
 Age, height, body mass, BMI, and physical activity were similar across groups 
(Table 1).  Participants with MS scored 4.6 ± 1.1 (range 3 to 6, out of a possible 10) in 
the sEDSS.  The MS group reported a significantly higher fatigue state (FSS) in the 
preceding 2 weeks compared with the control group, and a greater impact of fatigue on 
their lives (MFIS; Table 1).  Participants with MS had slower 7.62 m walk times at both 
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 brisk and preferred pace compared with controls (Table 1).  Two individuals with MS 
(1 female, 1 male) were unable to perform the fast treadmill walking speed and were 
statistically treated as missing data points.   
Energy Cost of Walking 
 The groups had similar VO2rest (MS: 2.82 ± 0.65 ml·kg-1·min-1, control: 2.71 ± 
0.85 ml·kg-1·min-1, p=0.72) and preferred walking speed (MS: 0.97 ± 0.28 m·s-1, 
control: 1.05 ± 0.17 m·s-1, p=0.42).  Overall, individuals with MS had higher Cw 
compared with controls across walking speeds (Figure 1; p=0.003).  A significant 
group-by-velocity interaction (p=0.03) showed that persons with MS had significantly 
higher Cw compared with controls during the slow, but not fast or preferred, walking 
speed (p=0.001).   
Symptomatic Fatigue and RPE 
 At baseline, the acute fatigue state was not different between groups (VAFS: 1.6 
± 1.0 in MS, 1.2 ± 0.4 in controls, p=0.72).  Overall, fatigue (Figure 2; p=0.001) and 
RPE (Figure 3; p=0.004) were higher in persons with MS compared with controls for all 
walking speeds.  There were no significant group-by-velocity interactions for fatigue 
(p=0.07) or RPE (p=0.11).  Notably, RPE was significantly associated with Cwpref 
(r=0.57, p=0.006) and Cwslow (r=0.41, p=0.05) but not Cwfast (r=0.26, p=0.22; Figure 4).  
There were no associations between VAFS and Cw at any speed (r≤ 0.35, p≥ 0.10; 
Figure 5). 
Physical Activity 
 Total daily physical activity counts were similar in MS and controls (Table 1).  
Physical activity was negatively associated with Cwslow (r=-0.44, p=0.03) and Cwfast 
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 (r=-0.55, p=0.008), but not Cwpref (r=-0.14, p=0.49; Figure 6).  Symptomatic fatigue 
was negatively associated with physical activity at all speeds (r≥ -0.49, p≤ 0.02).  
Ratings of perceived exertion were negatively associated with physical activity at slow 
(r=-0.52, p=0.01) and fast (r=-0.59, p=0.004), but not preferred (r=0.0, p=1.0), walking 
speeds. 
 
Discussion 
 We examined the energy cost of walking in persons with MS compared with 
age-matched controls.  In contrast to previous reports (93), we observed that Cw was 
higher at slow, but not preferred and fast, speed in persons with MS compared with 
controls.  This result indicates that persons with MS may adopt different strategies 
while walking at slow versus faster speeds to maintain postural control.  We also 
showed that symptomatic fatigue and perceived exertion were higher in persons with 
MS compared with controls, but only perceived exertion was associated with Cw.  
These results suggest that, in contrast to perceived exertion, symptomatic fatigue may 
not develop as a consequence of higher energy costs. 
Differential effects of speed on cost of walking in individuals with MS 
 Resting metabolic rate (VO2rest) was similar across groups, which has been 
shown previously (92; 93; 117).  We showed that Cw was higher during slow, but not 
fast or preferred, walking in persons with MS compared with age-matched controls.  
The lack of group differences in Cw during preferred and fast walking indicates a 
similar strategy in maintaining posture between groups.  Olgiati et al. (93) showed 
higher Cw in persons with MS compared with controls during treadmill walking at 2, 3, 
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 4, and 5 km·h-1 (0.6, 0.8, 1.1, and 1.4 m·s-1, respectively), regardless of speed.  In 
absolute terms, Cw in our MS group was lower than that reported by Olgiati et al. (93) 
(approximate range from slow to fast speeds: 0.33 to 0.22 ml·kg-1·m-1), which may be 
attributed to their sample population having greater mobility impairment (50% needed 
to use a walking aid) and, consequently, a greater need to activate more muscle to 
accomplish the task.  Greater mobility impairment has been associated with higher Cw 
(72).  Tantucci et al. (117) observed no difference in VO2 during an incremental 
exercise test using the cycle ergometer between controls and mildly-impaired persons 
with MS (EDSS 0.75 ± 0.30 SD).  The lack of difference in VO2 may be explained by a 
lower postural challenge in persons with MS when using the cycle ergometer versus the 
treadmill.   
 In our MS group, Cw was highest at slow walking and lowest at preferred 
walking speeds (Figure 1).  This pattern of Cw has been observed in spastic paresis 
(131) (MS, spinal cord injury, hemiparesis) and post-stroke (103) patients, suggesting 
that there may be greater muscular demand to maintain postural control during slow, 
rather than fast, walking in these neurological disease patients.  Studies have shown that 
postural control in MS during quiet stance is compromised (21; 47).  Altered functional 
strategies (minimal displacement of center of mass and smaller posterior shift in the 
center of pressure) have been observed during gait initiation in women with MS 
compared with controls (104), possibly to adjust for postural imbalances (21).  To date, 
no studies have measured Cw and gait characteristics, concurrently, at different walking 
speeds in persons with MS compared with controls. 
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  Although preferred treadmill speed was similar across groups, there was a large 
range of preferred treadmill speeds in both groups, which may be due to having to 
identify the preferred speed on the treadmill.   Persons with MS (1.31 ± 0.21 m·s-1) had 
lower usual 7.62 m walk speed over ground compared with controls (1.52 ± 0.19 m·s-1).  
Notably, the preferred treadmill speed was lower than the usual 7.62 m walk speed 
(p<0.001) in both groups.   
Symptomatic Fatigue and Perceived Exertion are impacted differently during walking 
in individuals with MS 
 Fatigue is a common, disabling symptom of MS (40).  As expected, general 
fatigue state (FSS) and the impact of fatigue on quality of life (MFIS) were higher in 
individuals with MS compared with controls.  Prior to the walking tests, acute fatigue 
(VAFS) did not differ between the MS and control groups.  However, at the end of each 
walking trial, both fatigue and perceived exertion were higher in persons with MS 
compared with controls (Figures 2 and 3).  However, acute fatigue was not associated 
with Cw, whereas perceived exertion was, suggesting that there may be other 
determinants (i.e., cognitive demands) affecting symptomatic fatigue than increased 
energy costs. 
 In contrast to our results, Morrison et al. (71) showed similar changes in 
perceived exertion and heart rate during a graded exercise test on a cycle ergometer 
between persons with MS and controls.  The differences in perceived exertion observed 
between studies may be due to differences in the severity of MS and testing protocol.  
Morrison et al.’s MS group had a median EDSS score of 2.75 (71) compared with our 
median of 4.5 on the self-reported EDSS instrument.  The difference in testing protocol 
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 (whole-body walking versus cycling) may also have contributed to differences in 
outcome.  Walking may demand more muscular activity to maintain upright posture 
than cycling in persons with MS compared with controls.  In addition, we prescribed 
absolute speeds, whereas Morrison et al. (71) had participants perform at relative 
workloads (% peak VO2), which may explain similar perceived exertion in persons with 
MS and controls.  We observed that RPE was related to Cw, indicating that higher 
perceived exertion may be explained by higher Cw. 
 Unexpectedly (although there was no VAFS-by-speed or RPE-by-speed 
interaction), fatigue and RPE were lowest during slow walking, where Cw was at its 
highest; and highest during preferred and fast walking, where Cw was at its lowest.  It is 
possible that fatigue and exertion worsened over time, given that the speeds were tested 
in order from slow to fast to preferred speeds.  However, if this were the case, we would 
expect an incremental increase in fatigue and exertion following each walking bout.  
Instead we observed that fatigue and perceived exertion were not different between fast 
and preferred walking speeds.  Because the preferred walking speed followed fast 
walking, it may be that the non-incremental increase in walking speed may have 
prevented any further exacerbation of fatigue and perceived exertion.   
Altered Cost of Walking by individuals with MS is not related to Physical Activity  
 In this study, our groups had similar habitual physical activity based on total 
daily accelerometer counts.  Using the same methodology, Ng and Kent-Braun (81) 
have shown lower physical activity in persons with MS (median EDSS score of 3.0) 
compared with controls.  This discrepancy may be because we tried to control physical 
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 activity level by recruiting individuals who were sedentary-to-recreationally active for 
both groups.   
 We observed that lower physical activity was related to higher Cw, suggesting 
that de-conditioning, rather than the symptoms of MS, may explain increased energy 
expenditure, given that we did not demonstrate group-specific differences in physical 
activity.  Persons with lower physical activity may be weaker and have less muscular 
coordination, which may require more muscular activity to accomplish a given task.  
Benedetti et al. (6) observed a decline in Cw at 4 and 6 km·h-1 (1.1 and 1.7 m·s-1) 
following a 4-week treadmill walking intervention in 3 MS patients.  In contrast, Olgiati 
et al. (92) observed no change in Cw in persons with MS, despite improvements in 
walking performance, following a 24-week physical therapy rehabilitation program.  
The discrepancy between these results may be the difference in the type of interventions 
(ramped treadmill walking exercise (6) versus general rehabilitation program (92)).  
Thus, increasing physical activity alone may not improve Cw in MS, but may depend 
on the type and intensity of the intervention.   
Limitations 
 The walking protocol was conducted on a treadmill because walking over 
ground at prescribed speeds is difficult to control.  In healthy adults, usual gait patterns 
that are normally observed while walking over ground may be altered (2) compared 
with walking on the treadmill at preferred speeds.  Despite potential gait characteristic 
differences between treadmill and over ground walking, elevated Cw is likely attributed 
to postural control challenges in MS. 
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  Another limitation to our walking protocol was that walking was conducted on 
the flat surface of a treadmill, whereas most walking environments are uneven.   Thus, it 
is not possible in this study to determine whether Cw would be altered in MS compared 
with controls in a more ecological environment.  However, the presence of sensory 
deficits in persons with MS could exacerbate this difference in Cw, as uneven surfaces 
could present an additional challenge to postural control during gait in these individuals. 
Conclusion 
 Differences in Cw in persons with MS, compared with age-matched controls, 
are higher at slow speeds but appear to be abolished at faster speeds.  Thus, slow 
walking may induce postural control challenges that require greater muscular work.  
Unlike perceived exertion, symptomatic fatigue appears to be dissociated from the 
energy costs of walking in MS.  Symptomatic fatigue and perceived exertion may have 
an impact on habitual physical activity behavior, although this does not seem to be 
related specifically to the presence of MS. 
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 Table 1.  Group Characteristics 
Data are presented as means ± S.D.  BMI, body mass index; CI, 95% confidence 
interval for the difference in means across groups.  FSS, fatigue severity scale.  MFIS, 
modified fatigue impact scale.  7.62 m walk time is for over ground walking.  CI for 
physical activity is not provided due to the use of non-parametric analysis to test for 
group differences. 
 
Variable 
Control  
(11F, 3M) 
MS  
(9F, 1M) 
CI p-value 
 
Age (years) 
 
46 ± 7 
 
45 ± 8 
 
-5.2, 7.7 
 
0.70 
Height (m) 1.68 ± 0.10 1.66 ± 0.06 -0.1, 0.1 0.47 
Body Mass (kg) 73.4 ± 16.3 74.4 ± 14.0 -14.3, 12.2 0.87 
BMI (m·kg-2) 25.7 ± 4.4 27.0 ± 4.5 -5.1, 2.5 0.50 
FSS 2.3 ± 1.1 4.3 ± 1.8 -3.2, -0.8 0.008 
MFIS 15 ± 15 40 ± 15 -37.1, -11.9 0.0007 
7.62 m walk time (s)  brisk 
  preferred 
3.9 ± 0.5 
5.1 ± 0.6 
4.7 ± 0.8 
6.0 ± 1.0 
-1.3, -0.2 
-1.6, -0.3 
0.02 
0.02 
Physical Activity  
(counts·day-1·1000-1) 
259 ± 146 209 ± 89 -- 0.63 
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 LIST OF FIGURES 
Figure 1.  Energy cost of walking at 3 speeds.  The cost of walking (Cw) was 
higher in persons with MS compared with controls, at all speeds (p=0.003).  * indicates 
a significant group-by-speed interaction, where Cw at 0.6 m·s-1 was higher in MS 
compared to controls (p=0.001).   Data are presented as means ± S.D.  Note that the 
order of trials was: slow, fast, preferred. 
Figure 2.  Acute symptomatic fatigue at 3 walking speeds.  Visual analog 
fatigue scale (VAFS) score was higher in persons with MS than controls for all walking 
speeds (p=0.001).  A VAFS score of 1 indicated “no fatigue” and 10 indicated “severe 
fatigue”.  Data are presented as means ± S.D.  Note that the order of trials was: slow, 
fast, preferred. 
Figure 3.  Ratings of perceived exertion at 3 walking speeds.  Rating of 
perceived exertion (RPE) score was higher in persons with MS than controls for all 
walking speeds (p=0.004).  A RPE score of 1 indicated “not tired at all” and 10 
indicated “so tired I cannot go anymore”.  Data are presented as means ± S.D.  Note that 
the order of trials was: slow, fast, preferred. 
Figure 4.  Relationship between RPE and energy cost of walking.  RPE was 
significantly associated with Cwpref and Cwslow, but not Cwfast.  Closed 
circles=control.  Open circles=MS. 
Figure 5.  Relationship between VAFS and energy cost of walking.  There 
were no associations between VAFS and Cw at any speed.  Closed circles=control.  
Open circles=MS. 
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 Figure 6.  Relationship between physical activity and energy cost of 
walking.  Physical activity was associated with the cost of walking (Cw) at a) slow 
(Cwslow) and c) fast (Cwfast) speeds, but not at b) preferred speed (Cwpref).  Closed 
circles=control.  Open circles=MS. 
 126
 Figure 1.  Energy cost of walking at 3 speeds 
Speed (m·s-1)
0.4 0.6 0.8 1.0 1.2 1.4 1.6
C
w
 (m
L·
kg
-1
·m
-1
)
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
Controls
MS
*
 
 127
 Figure 2.  Acute symptomatic fatigue at 3 walking speeds 
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 Figure 3.  Ratings of perceived exertion at 3 walking speeds 
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 Figure 4.  Relationship between RPE and energy cost of walking 
 
 
a)  
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
 
 
 
c) 
 
 
C
w
sl
ow
 (m
L·
kg
-1
·m
-1
)
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
C
w
pr
ef
 (m
L·
kg
-1
·m
-1
)
0.00
0.05
0.10
0.15
0.20
0.25
0.30
RPE
1 2 3 4 5 6 7 8 9 10
C
w
fa
st
 (m
L·
kg
-1
·m
-1
)
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
0.18
r=0.57, p=0.006
r=0.41, p=0.05
r=0.26, p=0.22
 130
 Figure 5.  Relationship between VAFS and energy cost of walking 
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 Figure 6.  Relationship between physical activity and energy cost of walking 
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 APPENDIX B 
LIST OF MEDICATIONS 
 
Medication Description  
  
Albeuterol bronchodilator 
Amantadine anti-viral agent 
Amoxicilin antibiotic 
Aricept reversible inhibitor of acetylcholinesterase 
Aspirin anti-inflammatory 
Avonex Immuno-modulator 
Baclofen muscle relaxant and anti-spastic agent 
Botox blocks nerve activity in muscle 
Celexa anti-depressant 
Cellcept immunosuppressive agent 
Claritin anti-histamine agent 
Copaxone reduce the frequency of relapses 
Detrol-LA treats symptoms of overactive bladder 
DHEA Precursor to sex hormones 
Diltiazem anti-hypertensive agent; Ca+-channel blocker 
Enablex treats symptoms of overactive bladder 
Flexeril muscle relaxant 
Fluoxetine anti-depressant 
Gabapentin anti-epileptic agent 
Hydrochlorothiazide anti-hypertensive agent; diuretic 
Imitrex treat migraines 
IV steroid treatment anti-inflammatory treatment to treat MS relapse 
Klonopin anti-epileptic agent 
Lexapro anti-depressant 
Lipitor cholesterol-lowering agent 
Lisinopril anti-hypertensive agent; ACE inhibitor 
Methotrexate anti-cancer agent 
Naltrexone narcotic drug that blocks the effects of other narcotics 
Neurotin anti-epileptic agent 
Nitrofurantoin antibiotic 
Oxytrol treats symptoms of overactive bladder 
Paroxetine anti-depressant 
Prilosec treats symptoms of gastroesophageal reflux disease 
Provigil promotes wakefulness 
Rebif immuno-modulator agent 
Ritalin mild CNS stimulant; improves attention 
Rituxan IV infusion Monoclonal antibody 
simvastatin cholesterol-lowering agent 
Synthroid treats hypothyroidism 
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 Trazadone anti-depressant 
Unithroid treats hypothyroidism 
Vesicare treats symptoms of overactive bladder 
Vitamin D vitamin D supplement 
Wellbutrin anti-depressant 
Xanax treats anxiety and panic disorder 
Zoloft anti-depressant 
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 APPENDIX C 
ASSOCIATIONS BETWEEN ISOMETRIC TORQUE, DYNAMIC POWER, 
AND PHYSICAL FUNCTION 
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 APPENDIX D 
COMPARISONS OF NEUROMUSCULAR VARIABLES BETWEEN NON-
SPASTIC AND PERSONS WITH SPASTICITY 
 
Variable Non-spastic With spasticity p value 
Peak Isometric Torque (Nm) 107 ± 31 109 ± 30 0.91 
Peak Power (W) 223 ± 71 204 ± 82 0.51 
mCSA (cm2) 44.7 ± 9.1 42.3 ± 4.9 0.52 
Specific Strength (Nm·cm-2) 2.41 ± 0.52 2.56 ± 0.46 0.58 
Specific Power (W·cm-2) 4.98 ± 1.18 4.79 ± 1.57 0.82 
maxMUDR (pps) 20.2 ± 5.8 27.2 ± 9.7 0.19 
Stimulated RFD (% peak force·ms-1) 1.10 ± 0.36 1.24 ± 0.46 0.58 
Voluntary-to-simulated RFD*100 (%) 58.1 ± 20.0 58.9 ± 26.3 0.95 
 
mCSA, fat-free muscle cross-sectional area; maxMUDR, maximal motor unit discharge 
rate; RFD, maximal rate of force development. 
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 APPENDIX E 
ASSOCIATIONS BETWEEN SPASTICITY AND PHYSICAL FUNCTION IN 
PERSONS WITH MS 
y = non-spastic            ○ = persons with spasticity 
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  APPENDIX F 
ANCILLARY MEASURES TO CHAPTER 5 
 
 To further characterize contractile function, the maximal rate of force relaxation (% 
peak force·ms-1) was determined from the first derivative of the torque trace.  The 
maximal rate of force relaxation was slower in persons with MS (-0.71 ± 0.22 % 
peak force·ms-1) compared with controls (-1.05 ± 0.32 % peak force·ms-1, 
p=0.0005).  These results suggest slowing of calcium re-sequestration to the 
sarcoplasmic reticulum in persons with MS compared with controls. 
 To examine maxMUDR at submaximal intensities, participants were asked to 
perform three 50% MVICs (4-5 s duration), with 2 min of rest between trials. 
Additional 50% MVIC trials were performed if there were less than 3 trials with 
clear recordings.  A total of 138 motor units were identified (72 for controls and 66 
for MS) at 50% MVIC.  Three participants (2 controls, 1 MS) were unable to 
perform the intramuscular EMG protocol at 50% MVIC due to non-significant 
adverse event (e.g. feeling faint).  Average torque achieved when asked to perform 
50% MVIC was 50 ± 3 % for both controls and MS during MUDR recordings.  
Lower maxMUDR at 50% MVIC were observed in persons with MS (16.0 ± 4.6 
pps) compared with controls (20.4 ± 5.9 pps, p=0.04).  These results agree with 
Dorfman et al. (33), who observed lower maxMUDR at submaximal intensity 
contractions in persons with MS compared with controls. 
 We also measured mean MUDR, which was calculated by averaging all interpulse 
intervals of a given motor unit during the plateau phase of each contraction, at 100% 
and 50% MVIC.  There was no difference in mean MUDR at 100% MVIC across 
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 groups (controls: 18.6 ± 5.1 pps, MS: 16.3 ± 5.7 pps, p=0.24).  At 50% MVIC, 
lower mean MUDR were observed in persons with MS (10.8 ± 2.0 pps) compared 
with controls (13.8 ± 3.8 pps, p=0.02). 
 We indirectly compared motor unit recruitment strategies by taking the ratio of 
MUDR between 100% and 50% MVIC for each participant.  There were no 
differences across groups in the ratio of maximal (controls: 1.37 ± 1.38, and MS: 
1.38 ± 0.23, p=0.87) and mean (controls: 1.33 ± 0.19, MS: 1.46 ± 0.32, p=0.23) 
MUDR at 100% and 50% MVIC. 
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 APPENDIX G 
TABLE OF UNIT CONVERSIONS 
 
m·s-1 km·hr-1 miles·hr-1   
0.17 0.61 0.38 
0.19 0.68 0.43 
0.21 0.76 0.47 
0.28 1.00 0.63 
0.56 2.00 1.24 
0.60 2.16 1.34 
0.83 3.00 1.86 
0.97 3.49 2.17 
1.05 3.78 2.35 
1.11 4.00 2.49 
1.31 4.72 2.93 
1.39 5.00 3.11 
1.40 5.04 3.13 
1.52 5.47 3.40 
1.67 6.00 3.73 
   
m ft   
7.62 25  
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 APPENDIX H 
PARTICIPANT FORMS 
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 INFORMED CONSENT DOCUMENT 
 
University of Massachusetts 
Amherst, MA 01003 
 
Project Title:  Mechanisms of Muscle Weakness in Persons with Multiple Sclerosis 
 
Principal Investigator: Linda Chung, M.S.   
Co-Investigators:  Jane Kent-Braun, Ph.D., Richard van Emmerik, Ph.D. 
      
Your written informed consent is required before you can participate in this project.  
Please read this document carefully and then sign your name on the last page if you 
agree to participate.  This document is in accordance with the General Policy on the 
Rights and Welfare of Human Subjects, as approved by the Faculty Senate of the 
University of Massachusetts. 
 
Purpose:  To systematically determine the causes of reduced muscle strength and 
power, and how it impacts energy expenditure, physical function and symptomatic 
fatigue in persons with MS. 
 
Eligibility:  To participate in this study, you must  
1) be between the ages of 30 and 60 years 
2) be free from metabolic, non-MS neurologic, cardiovascular or other major 
disease 
3) not be taking any medications (other than for MS) that may affect muscle 
function (i.e., beta blockers, sedatives, anti-cholesterol medications, etc.) 
4) have a visual acuity of 20/200 or better 
5) participate in less than three 30-minute structured exercise sessions per week 
6) not be pregnant 
7) not have cognitive impairment or a mental disorder that precludes following 
instructions 
8) not have significant arthritis in the lower extremities 
9) have no history of breathing difficulties, cramping, light-headedness or other 
symptoms of exertion 
10) not be a smoker 
11) not have oculomotor and/or cerebellar disorders  
12) have no history of claustrophobia  
13) not have pieces of metal in your body (such as fragment(s) in the eye, 
aneurysm clips, ear implants, spinal nerve stimulator, and pacemaker) 
All persons with MS must also have clinically verified MS (any subtype). 
 
Procedures:  Prior to your participation in this study, you will be screened by telephone 
interview for general health status, medical history, current medications and usual 
physical activity habits.  If you are qualified and agree to participate in the study, the 
following table outlines the measures we’ll be making in each visit.  Each visit will be 
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 separated by 3 to 7 days.  A more detailed explanation of each of the measures are 
described below the table. 
 
Visit # Measures Location Duration 
1  Questionnaires 
 Anthropometrics 
 Blood pressure 
 Physical function 
 Familiarization of dynamometer protocols 
 Activity monitor instructions 
Muscle Physiology 
Lab at UMass-
Amherst 
2.5 hours 
2  Dynamometer protocols on both legs 
 Passive resistance 
 Isometric contractions 
 Isovelocity contractions 
 Electrical stimulation 
Muscle Physiology 
Lab at UMass-
Amherst 
2.5 hours 
3 Intramuscular electromyography on both legs Exercise 
Neuroscience Lab 
at UMass-Amherst 
1.5 hours 
4 MRI of both legs  MRI Center 
Cooley Dickinson 
Hospital in 
Amherst 
1.5 hours 
 
Questionnaires.  You will be asked to complete the following questionnaires: medical 
history, self-reported expanded disability status score, modified fatigue impact 
scale, visual analog fatigue scale, spasticity scale, and physical activity readiness.  
You will also be asked to complete the magnetic resonance safety form to determine 
your eligibility to enter the MRI room.   
 
Anthropometrics.  We will measure your height, weight, and length of your lower limb. 
 
Blood pressure.  We will measure your blood pressure at the arm while you are lying 
down on a bed. 
 
Physical Function.  Your level of physical function will be measured using the 
following performance tests, which the investigator will demonstrate for you: 
 Metabolic Rate While Walking 
- We will measure how much energy you expend while walking 
at 3 different speeds.  To do this, we will first measure your 
resting metabolic rate (following an overnight fast).  You will 
lay on a bed with a ventilated hood placed over your head for 
20 minutes.  The ventilated hood will measure the difference in 
oxygen between the air you breathe in and the air you breathe 
out during normal breathing. 
- Next, you will be asked to breathe through a mouthpiece, which 
will be connected to an indirect calorimeter via a hose, so that 
we can measure your metabolic rate while you are walking.  
You will be asked to walk on a treadmill at a self-selected 
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 pace, and at slow and fast speeds, for 4 minutes each.  You will 
be given 5-10 minutes of seated rest between walking tests. 
 Walking speed 
- You will be asked to walk 25 feet twice, once at a self-selected 
pace and once at a brisk pace. 
 Leg function 
- To assess your leg strength, we will ask you to perform rapid 
chair rises 5 times  
 Foot tap speed 
- You will be asked to perform rapid foot taps for 10 seconds for 
each foot. 
 
Familiarization to dynamometer protocols.  A dynamometer is an instrument that lets 
us measure the force your muscles produce while your leg is static, or moving at a fixed 
speed.  You will be seated in a chair with your upper body secured with seat belt straps.  
Your lower leg will be secured to a rotating apparatus using Velcro.  Using one of your 
legs, we will then familiarize you with the contraction protocols that you will perform 
(see Dynamometer Protocols below), so that you are comfortable with the procedures. 
 
Activity Monitor.  At the end of your Visit 1, you will be asked to wear an activity 
monitor around your waist for 7 days during waking hours.  The activity monitor is 
a small plastic device (about the size of a pager) that measures vertical 
accelerations, and will give us an idea of your daily physical activity level.  You 
will also be asked to keep a simple diary of your physical activities.  You will return 
the activity monitor and diary on your next visit. 
 
Dynamometer protocols.  Prior to being seated on the dynamometer, you will be asked 
to warm-up your leg muscles by cycling on a recumbent bike for 2 minutes without 
any resistance.  Following this warm-up, we will tape small electromyography 
electrodes to the skin on the front and back sides of your thigh, as well as on the 
bony part of your knee.  Surface electromyography electrodes will measure the 
electrical activity from your muscles.  Once you are seated and secured to the 
dynamometer (see Familiarization of Dynamometer Protocols), you will perform the 
following protocols:  
 
-  Passive resistance.  While you are relaxed, the dynamometer will extend and flex 
your knee over a set range of motion at different speeds.  The data obtained from 
this protocol will give us information about spasticity, which is defined as 
increased muscle tone or stiffness due to a hyper-excitable reflex. 
 
-  Isometric contractions.  You will perform 3 to 4 static, maximal contractions of 
your quadriceps muscles (front of the thigh).  Each contraction will last no 
longer than 5 seconds.  You will repeat this with the hamstring muscles (back of 
the thigh). 
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 -  Isovelocity contractions.  You will perform maximal voluntary contractions by 
extending your knee against different speeds of resistance.  Your leg will move 
during muscle contraction, but the movement of your leg will be limited to a 
fixed range. 
 
-  Electrical stimulation.  In addition to the surface electromyography electrodes, 2 
flexible stimulating pads will be placed over your thigh.  These pads are 
designed to stimulate your muscle to contract without any effort on your part, 
which will give us information about your muscle’s function.  We will set the 
intensity of the stimulation to produce a force level that is 50% of your 
maximum voluntary strength.  Once the intensity is set, we will give you a burst 
of stimuli that lasts 1 second while your leg remains in a static position and you 
stay relaxed.  We will apply the same burst 2 more times, with 2 minutes of rest 
between each burst. 
 
Intramuscular Electromyography.  Like surface electromyography, electrical activity 
from your muscle will be measured using a small, sterilized needle electrode placed 
directly into your muscle.  It will remain there for ~30-40 min.  This will provide us 
precise information about your muscle activation.  Electrical signals during 
submaximal and maximal voluntary isometric contractions will be recorded.  To 
obtain clear electrical signals, slight adjustments of the electrode will be made.  This 
procedure will be performed in the Exercise Neuroscience Lab, just down the hall 
from the Muscle Physiology Lab, and will be done in both legs. 
 
MRI.  An MRI of your thighs will be taken at the Cooley Dickinson Hospital MRI 
Center on University Drive in Amherst.  We will provide transportation to Cooley 
Dickinson for you, if you wish.  You will be asked to complete a brief medical 
history form and Magnetic Materials Safety questionnaire to ensure that there are no 
magnetic materials in your body.  After we ensure that you are free of magnetic 
objects, you will be taken into the MRI room, where you will lie on the MRI bed 
and have your leg centered inside a circular coil.  This coil, which is shaped like a 
small tube, will allow us to obtain information about the size and shape of your 
muscles, using radio waves and a superconducting magnet.  To protect your hearing 
during the imaging, you will be given earplugs or headphones to wear.  After you 
are positioned comfortably, we will slide the MRI bed into the scanner.  We will 
then collect anatomical images of your leg.  While acquiring images, the table may 
shake slightly, and you will hear loud knocking noises.  This is a normal part of the 
imaging procedure.  This procedure will take approximately 30 minutes per leg and 
both legs will be imaged. 
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 Possible Risks and Discomforts:  The following risks and discomforts are associated 
with the procedures described above.   
 
Isometric and isovelocity contractions.  Although we will try to give you enough rest in 
between contractions, you may develop some muscle fatigue.  You may also 
experience some soreness following the voluntary contractions, which may come 
about immediately or later in the day.  The soreness is normal and will subside in a 
couple of days.  The soreness should not affect your normal daily activities. 
 
Electrical stimulation. Although stimulation is brief, you may experience some 
discomfort. 
 
Intramuscular Electromyography.  Insertion of the electrode into the muscle will be 
uncomfortable.  However, the discomfort should dissipate after about a minute.  If 
the discomfort persists, then slight adjustments can be made to relieve any 
discomfort.  Like any foreign body, the needle electrode poses a risk for infection.  
This electrode is thoroughly gas-sterilized before it is used.  In our experience, no 
individual has ever experienced adverse consequences from this electrode.  It is 
possible that you may experience nausea, feel faint, and, though extremely rare, lose 
consciousness.  In the event of such experiences, the session will be terminated and 
all proper measures will be made to ensure your comfort and safety. 
 
MRI. When in the magnet, there is a very small possibility that the magnetic field will 
pull an iron-containing object into the magnet, which might result in physical injury.  
However, precautions have been taken to prevent such an event from happening; all 
subjects will walk through a metal detector to ensure that no loose metal objects, 
like pocketknives or key chains, are brought into the magnet room.  If you have a 
piece of metal in your body, such as fragment in your eye, aneurysm clips, ear 
implants, spinal nerve stimulators, or a pacemaker, you will not be allowed into the 
magnet room and cannot participate in this study.  One potential hazard of having an 
MRI is heating of the body due to the radio waves that we use.  However, the MRI 
machine has safety devices that will prevent this from happening.  Women, who are 
pregnant, or trying to conceive, are discouraged from participating in MRI studies 
due to the potential risks associated with this procedure.  Your head will be at the 
opening of the magnet; however, you may be bothered by feelings of claustrophobia 
or by the load noise during the MRI session.  Temporary hearing loss has been 
reported from this loud noise, so you will be asked to wear earplugs or headphones.  
If at any time you feel too claustrophobic or too uncomfortable to continue, the MRI 
session will be stopped immediately. 
 
Confidentiality:  Your identity and records will be kept confidential.  While results 
from this study will be shared with other researchers, no individual identities will be 
used in any reports or publications resulting from this study. 
 
In Case of Injury:  In the unlikely event of injury, resulting directly from participation 
in this study, we will do everything we can to assist you in seeking medical treatment.  
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 The University of Massachusetts will not provide compensation for medical treatment 
you obtain. 
 
Benefits:  You will receive no direct benefit from participating in this study.  Any 
information that is obtained from this study will be made available to your physician, 
upon request.  The purpose of this study is to provide the investigators with information 
that will help us understand the mechanisms of muscle weakness in persons with MS.  
This study may provide an evidence-based rationale for specially-designed exercise 
therapies improving muscle strength and power in persons with MS. 
 
Costs and Reimbursement:  You will receive $100 for completing this study.  A check 
will be mailed to your home approximately six weeks after your last visit.  In the event 
that you do not complete the study, partial compensation will be provided as follows: 
$10 for visit 1 only, $30 each for visits 2, 3, and 4.  This study is supported by an 
ACSM Foundation Research Grant (FRG) from the American College of Sports 
Medicine Foundation and the National Multiple Sclerosis Society. 
 
Withdrawal of Participation:  Participation in this research is voluntary.  You have 
the right to withdraw from this study at any time, for any reason.  
 
Information:  You are encouraged to ask questions about the study.  The investigators 
will attempt to answer all of your questions to the best of their knowledge.  The 
investigators fully intend to conduct the study with your best interest, safety and 
comfort in mind.  Please address any questions regarding the study to Linda Chung, 
M.S. (413) 545-5305, Dr. Jane Kent-Braun, Ph.D. (413) 545-9477, or Dr. Richard van 
Emmerik Ph.D. (413) 545-0325.  If you would like to speak with someone not directly 
involved in the research study, you may contact the Human Research Protection Office 
at the University of Massachusetts via email at humansubject@ora.umass.edu; 
telephone (413) 545-3428; or mail at the Human Research Protection Office, Research 
Administration Building, University of Massachusetts Amherst, 70 Butterfield Terrace, 
Amherst, MA 01003-9242. 
 
 
Participant’s Name    Address 
 
 
Signature    Date     Phone Number 
 
 
Linda Chung, M.S. 
 
 
Jane Kent-Braun, Ph.D. or Richard van Emmerik, Ph.D.  
 
 147
 Medical History Form 
 
Please fill out and sign in ink.  This record is confidential. 
 
Name (print):___________________________  Date:__________________ 
 
Signature:_________________________________ 
 
Medical History 
Are you taking any prescribed or over-the-counter medications?  Please include 
vitamins, herbs or other dietary supplements.  If yes, please list dose, frequency and 
duration of use. 
______________________________________________________________________
______________________________________________________________________ 
 
Have you ever been told by a physician that you should not exercise?  
Yes_____No_____ 
If yes, please explain: ____________________________________________________ 
______________________________________________________________________
______________________________________________________________________ 
 
Do you or have you EVER had any of the following problems?  Check if YES and 
provide details below. 
 
____Heart disease/rheumatic fever   ____Thyroid disorder  ____Asthma 
____High blood pressure    ____Claustrophobia  ____Allergies 
____Elevated cholesterol    ____Anemia   ____Stroke 
____Epilepsy or seizure disorder   ____Diabetes   ____Dizziness 
____Blurred or double vision 
____Orthopedic or joint problems (e.g., arthritis) 
____Shortness of breath or difficulty in breathing 
____Phlebitis, blood clots, varicose veins, peripheral vascular disease 
 
Details:________________________________________________________________
______________________________________________________________________ 
 
Lifestyle 
Do you smoke cigarettes?  Yes____ No____ 
Do you drink alcohol?  Yes____ No____ 
Do you exercise regularly?  Yes____ No____  
If yes, number of times per week_____ 
Have you had surgery?  Yes____ No____ 
     If yes, when was this?___________________ 
 
Is there any other information or concern you have that you feel we should know about 
before you participate in the study?  If so, please explain.  
______________________________________________________________________
______________________________________________________________________ 
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 PHYSICAL ACTIVITY READINESS QUESTIONNAIRE 
 
1. Has a doctor ever said you have a heart condition and recommended only 
medically supervised activity? 
Yes____ No____ 
 
2. Do you have chest pain brought on by physical activity? 
 
Yes____ No____ 
 
3. Have you developed chest pain in the last month? 
 
Yes____ No____ 
 
4. Do you tend to lose consciousness or fall over as a result of dizziness? 
 
Yes____ No____ 
 
5. Do you have a bone or joint problems that could be aggravated by the proposed 
physical activity? 
 
Yes____ No____ 
 
6. Has a doctor ever recommended medication for your blood pressure or a heart 
condition? 
 
Yes____ No____ 
 
7. Are you aware through your own experience, or a doctor’s advice, of any other 
physical reason against your exercising without medical supervision? 
 
Yes____ No____ 
 
 
NOTE:  If you have a temporary illness, such as a common cold, or are not feeling well 
at this time – POSTPONE. 
 
 
NAME_______________________________ DATE_________________ 
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